2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary

A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions

WRITING COMMITTEE MEMBERS*

Glenn N. Levine, MD, FACC, FAHA, Chair†; Eric R. Bates, MD, FACC, FAHA, Vice Chair*†;
James C. Blankenship, MD, FACC, FSCAI, Vice Chair*‡;
Steven R. Bailey, MD, FACC, FSCAI*‡; John A. Bittl, MD, FACC†§;
Bojan Cercek, MD, FACC, FAHA†; Charles E. Chambers, MD, FACC, FSCAI‡;
Stephen G. Ellis, MD, FACC*†; Robert A. Guyton, MD, FACC*‡;
Steven M. Hollenberg, MD, FACC, FAHA*‡; Umesh N. Khot, MD, FACC*†;
Richard A. Lange, MD, FACC, FAHA§; Laura Mauri, MD, MSC, FACC, FSCAI†;
Roxana Mehran, MD, FACC, FAHA, FSCAI*‡; Issam D. Moussa, MD, FACC, FAHA, FSCAI‡;
Debabrata Mukherjee, MD, FACC, FSCAI†;
Brahmajee K. Nallamothu, MD, FACC¶; Henry H. Ting, MD, FACC, FAHA†

ACCF/AHA TASK FORCE MEMBERS

Alice K. Jacobs, MD, FACC, FAHA, Chair; Jeffrey L. Anderson, MD, FACC, FAHA, Chair-Elect;
Nancy Albert, PhD, CCNS, CCRN, FAHA; Mark A. Creager, MD, FACC, FAHA;
Steven M. Ettinger, MD, FACC; Robert A. Guyton, MD, FACC;
Jonathan L. Halperin, MD, FACC, FAHA; Judith S. Hochman, MD, FACC, FAHA;
Frederick G. Kushner, MD, FACC, FAHA; E. Magnus Ohman, MD, FACC;
William Stevenson, MD, FACC, FAHA; Clyde W. Yancy, MD, FACC, FAHA

*Writing committee members are required to recuse themselves from voting on sections where their specific relationship with industry and other entities may apply; see Appendix 1 for recusal information.
†ACCF/AHA Representative.
‡SCAI Representative.
§Joint Revascularization Section Author.
¶ACCF/AHA Task Force on Practice Guidelines Liaison.
‖ACCF/AHA Task Force on Performance Measures Liaison.

This document was approved by the American College of Cardiology Foundation Board of Trustees and the American Heart Association Science Advisory and Coordinating Committee in July 2011 and the Society for Cardiovascular Angiography and Interventions in August 2011.


This article has been copublished in the Journal of the American College of Cardiology and Catheterization and Cardiovascular Interventions.

Copies: This document is available on the World Wide Web sites of the American College of Cardiology (www.cardiosource.org), the American Heart Association (my.americanheart.org), and the Society for Cardiovascular Angiography and Interventions (www.scai.org). A copy of the document is available at http://my.americanheart.org/statementselect allowed to use the “By Topic” link or the “By Publication Date” link. To purchase additional reprints, call 843-216-2533 or e-mail kelle.ramsay@wolterskluwer.com.

Expert peer review of AHA Scientific Statements is conducted at the AHA National Center. For more on AHA statements and guidelines development, visit http://my.americanheart.org/statementselect and the “Policies and Development” link.

Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American Heart Association. Instructions for obtaining permission are located at http://www.heart.org/HEARTORG/General/Copyright-Permission-Guidelines_UCM_300404_Article.jsp. A link to the “Copyright Permissions Request Form” appears on the right side of the page.

(Circulation. 2011;124:2574–2609.)

© 2011 by the American College of Cardiology Foundation and the American Heart Association, Inc.

Circulation is available at http://circ.ahajournals.org

DOI: 10.1161/CIR.0b013e31823a5596

2574
Table of Contents

Preamble ................................... 2575
1. Introduction ............................. 2578
   1.1. Methodology and Evidence Review ........ 2578
   1.2. Organization of the Writing Committee .... 2578
   1.3. Document Review and Approval ............ 2578
   1.4. PCI Guideline Scope ................... 2578
2. CAD Revascularization: Recommendations .... 2578
   2.1. Heart Team Approach to Revascularization ... 2580
   2.2. Revascularization to Improve Survival ..... 2580
   2.3. Revascularization to Improve Symptoms ... 2581
   2.4. Clinical Factors That May Influence the Choice of Revascularization .... 2582
   2.4.1. Dual Antiplatelet Therapy Compliance and Stent Thrombosis .... 2582
   2.5. Hybrid Coronary Revascularization ......... 2582
3. Preprocedural Considerations: Recommendations ... 2582
   3.1. Radiation Safety ..................... 2582
   3.2. Contrast-Induced Acute Kidney Injury .... 2583
   3.3. Anaphylactoid Reactions ................ 2583
   3.4. Statin Treatment ...................... 2583
   3.5. Bleeding Risk ........................ 2583
   3.6. PCI in Hospitals Without On-Site Surgical Backup ................ 2583
4. Procedural Considerations: Recommendations .... 2583
   4.1. Vascular Access ....................... 2583
   4.2. PCI in Specific Clinical Situations ....... 2583
   4.2.1. Unstable Angina/Non–ST-Elevation Myocardial Infarction .... 2583
   4.2.2. ST-Elevation Myocardial Infarction .... 2584
   4.2.3. Cardiogenic Shock .................. 2585
   4.2.4. Revascularization Before Noncardiac Surgery ................ 2585
   4.3. Coronary Stents ....................... 2586
   4.4. Adjunctive Diagnostic Devices .......... 2586
   4.4.1. Fractional Flow Reserve .............. 2586
   4.4.2. Intravascular Ultrasound ............. 2586
   4.5. Adjunctive Therapeutic Devices .......... 2586
   4.5.1. Coronary Atherectomy ............... 2586
   4.5.2. Thrombectomy ....................... 2586
   4.5.3. Laser Angioplasty ................... 2587
   4.5.4. Cutting Balloon Angioplasty ........... 2587
   4.5.5. Embolic Protection Devices .......... 2587
   4.6. Percutaneous Hemodynamic Support Devices .... 2587
   4.6.1. Oral Antiplatelet Therapy .......... 2588
   4.6.2. Intravenous Antiplatelet Therapy .... 2588
   4.6.3. Anticoagulant Therapy .............. 2589
   4.6.4. No-Reflow Pharmacological Therapies .... 2589
   4.7. PCI in Specific Anatomic Situations ....... 2589
   4.7.1. Chronic Total Occlusions ............ 2589
   4.7.2. Saphenous Vein Grafts .............. 2589
   4.7.3. Bifurcation Lesions .................. 2589
   4.7.4. Aorto-Ostial Stenoses .............. 2589
   4.7.5. Calcified Lesions ................... 2591
   4.8. PCI in Specific Patient Populations ....... 2591
   4.8.1. Chronic Kidney Disease ............... 2591
   4.9. Periprocedural Myocardial Infarction Assessment ............. 2591
   4.10. Vascular Closure Devices .............. 2591
5. Postprocedural Considerations: Recommendations .... 2591
   5.1. Postprocedural Antiplatelet Therapy ....... 2591
   5.1.1. Proton Pump Inhibitors and Antiplatelet Therapy .............. 2591
   5.1.2. Clopidogrel Genetic Testing .......... 2592
   5.1.3. Platelet Function Testing .......... 2592
   5.2. Restenosis ................................ 2592
   5.2.1. Exercise Testing .................... 2592
   5.2.2. Cardiac Rehabilitation ............... 2592
6. Quality and Performance Considerations: Recommendations ........... 2592
   6.1. Quality and Performance ................ 2592
   6.2. Certification and Maintenance of Certification .... 2592
   6.3. Operator and Institutional Competency and Volume ............ 2592
References ................................ 2593
Appendix 1. Author Relationships With Industry and Other Entities (Relevant) .... 2605
Appendix 2. Reviewer Relationships With Industry and Other Entities (Relevant) .... 2608

Preamble

The medical profession should play a central role in evaluating the evidence related to drugs, devices, and procedures for the detection, management, and prevention of disease. When properly applied, expert analysis of available data on the benefits and risks of these therapies and procedures can improve the quality of care, optimize patient outcomes, and favorably affect costs by focusing resources on the most effective strategies. An organized and directed approach to a thorough review of evidence has resulted in the production of clinical practice guidelines that assist physicians in selecting the best management strategy for an individual patient. Moreover, clinical practice guidelines can provide a foundation for other applications, such as performance measures, appropriate use criteria, and both quality improvement and clinical decision support tools.

The American College of Cardiology Foundation (ACCF) and the American Heart Association (AHA) have jointly produced guidelines in the area of cardiovascular disease since 1980. The ACCF/AHA Task Force on Practice Guidelines (Task Force), charged with developing, updating, and revising practice guidelines for cardiovascular diseases and procedures, directs and oversees this effort. Writing committees are charged with regularly reviewing and evaluating all available evidence to develop balanced, patient-centric recommendations for clinical practice.

Experts in the subject under consideration are selected by the ACCF and AHA to examine subject-specific data and

Downloaded from http://circ.ahajournals.org/ by guest on June 7, 2017
write guidelines in partnership with representatives from other medical organizations and specialty groups. Writing committees are asked to perform a formal literature review; weigh the strength of evidence for or against particular tests, treatments, or procedures; and include estimates of expected outcomes where such data exist. Patient-specific modifiers, comorbidities, and issues of patient preference that may influence the choice of tests or therapies are considered. When available, information from studies on cost is considered, but data on efficacy and outcomes constitute the primary basis for the recommendations contained herein.

In analyzing the data and developing recommendations and supporting text, the writing committee uses evidence-based methodologies developed by the Task Force. The Class of Recommendation (COR) is an estimate of the size of the treatment effect considering risks versus benefits in addition to evidence and/or agreement that a given treatment or procedure is or is not useful/effective or in some situations may cause harm. The Level of Evidence (LOE) is an estimate of the certainty or precision of the treatment effect. The writing committee reviews and ranks evidence supporting each recommendation with the weight of evidence ranked as LOE A, B, or C according to specific definitions that are included in Table 1. Studies are identified as observational, retrospective, prospective, or randomized where appropriate.

For comparative effectiveness recommendations (Class I and IIa; Level of Evidence A and B only), studies that support the use of comparator verbs should involve direct comparisons of the treatments or strategies being evaluated.

<table>
<thead>
<tr>
<th>SIZE OF TREATMENT EFFECT</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLASS I</td>
</tr>
<tr>
<td>Benefit &gt;&gt; &gt;&gt; Risk</td>
</tr>
<tr>
<td>Procedure/Treatment</td>
</tr>
<tr>
<td>SHOULD be performed/</td>
</tr>
<tr>
<td>administered</td>
</tr>
<tr>
<td>CLASS IIa</td>
</tr>
<tr>
<td>Benefit &gt;&gt; Risk</td>
</tr>
<tr>
<td>Additional studies with</td>
</tr>
<tr>
<td>focused objectives needed</td>
</tr>
<tr>
<td>IT IS REASONABLE to</td>
</tr>
<tr>
<td>perform procedure/administer</td>
</tr>
<tr>
<td>treatment</td>
</tr>
<tr>
<td>CLASS IIb</td>
</tr>
<tr>
<td>Benefit ≥ Risk</td>
</tr>
<tr>
<td>Additional studies with</td>
</tr>
<tr>
<td>broad objectives needed;</td>
</tr>
<tr>
<td>additional registry data</td>
</tr>
<tr>
<td>would be helpful</td>
</tr>
<tr>
<td>Procedure/Treatment</td>
</tr>
<tr>
<td>MAY BE CONSIDERED</td>
</tr>
<tr>
<td>CLASS III</td>
</tr>
<tr>
<td>No Benefit or CLASS III</td>
</tr>
<tr>
<td>Harm</td>
</tr>
<tr>
<td>Procedure/</td>
</tr>
<tr>
<td>Test</td>
</tr>
<tr>
<td>Treatment</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ESTIMATE OF CERTAINTY (PRECISION) OF TREATMENT EFFECT</th>
</tr>
</thead>
<tbody>
<tr>
<td>LEVEL A</td>
</tr>
<tr>
<td>Multiple populations evaluated*</td>
</tr>
<tr>
<td>Data derived from multiple randomized clinical trials</td>
</tr>
<tr>
<td>or meta-analyses</td>
</tr>
<tr>
<td>Recommendation that procedure or treatment is</td>
</tr>
<tr>
<td>useful/effective</td>
</tr>
<tr>
<td>Sufficient evidence from multiple randomized trials</td>
</tr>
<tr>
<td>or meta-analyses</td>
</tr>
<tr>
<td>CLASS B</td>
</tr>
<tr>
<td>Limited populations evaluated*</td>
</tr>
<tr>
<td>Data derived from a single randomized trial</td>
</tr>
<tr>
<td>or nonrandomized studies</td>
</tr>
<tr>
<td>Recommendation that procedure or treatment is</td>
</tr>
<tr>
<td>useful/effective</td>
</tr>
<tr>
<td>Evidence from single randomized trial or</td>
</tr>
<tr>
<td>nonrandomized studies</td>
</tr>
<tr>
<td>Recommendation that procedure or treatment is</td>
</tr>
<tr>
<td>useful/effective</td>
</tr>
<tr>
<td>Some conflicting evidence from single randomized</td>
</tr>
<tr>
<td>trials or meta-analyses</td>
</tr>
<tr>
<td>CLASS C</td>
</tr>
<tr>
<td>Very limited populations evaluated*</td>
</tr>
<tr>
<td>Only consensus opinion of experts, case studies, or</td>
</tr>
<tr>
<td>standard of care</td>
</tr>
<tr>
<td>Recommendation that procedure or treatment is</td>
</tr>
<tr>
<td>useful/effective</td>
</tr>
<tr>
<td>Only expert opinion, case studies, or standard of</td>
</tr>
<tr>
<td>care</td>
</tr>
<tr>
<td>Recommendation that procedure or treatment is</td>
</tr>
<tr>
<td>useful/effective</td>
</tr>
<tr>
<td>Only diverging expert opinion, case studies, or</td>
</tr>
<tr>
<td>standard of care</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Suggested phrases for writing recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>should is recommended</td>
</tr>
<tr>
<td>is indicated</td>
</tr>
<tr>
<td>is useful/effective/beneficial</td>
</tr>
<tr>
<td>Comparative effectiveness phrases*</td>
</tr>
<tr>
<td>treatment strategy A is recommended/indicated in</td>
</tr>
<tr>
<td>preference to treatment B</td>
</tr>
<tr>
<td>treatment A should be chosen over treatment B</td>
</tr>
<tr>
<td>treatment strategy A is probably recommended/indicated</td>
</tr>
<tr>
<td>in preference to treatment B</td>
</tr>
<tr>
<td>it is reasonable to choose treatment A over treatment B</td>
</tr>
</tbody>
</table>

A recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the guidelines do not lend themselves to clinical trials. Although randomized trials are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful or effective.

*Data available from clinical trials or registries about the usefulness/efficacy in different subpopulations, such as sex, age, history of diabetes, history of prior myocardial infarction, history of heart failure, and prior aspirin use.

†For comparative effectiveness recommendations (Class I and IIa; Level of Evidence A and B only), studies that support the use of comparator verbs should involve direct comparisons of the treatments or strategies being evaluated.
mendations at LOE C are supported by historical clinical data, appropriate references (including clinical reviews) are cited if available. For issues for which sparse data are available, a survey of current practice among the clinicians on the writing committee is the basis for LOE C recommendations and no references are cited. The schema for COR and LOE is summarized in Table 1, which also provides suggested phrases for writing recommendations within each COR. A new addition to this methodology is separation of the Class III recommendations to delineate if the recommendation is determined to be of “no benefit” or is associated with “harm” to the patient. In addition, in view of the increasing number of comparative effectiveness studies, comparator verbs and suggested phrases for writing recommendations for the comparative effectiveness of one treatment or strategy versus another have been added for COR I and IIa, LOE A or B only.

In view of the advances in medical therapy across the spectrum of cardiovascular diseases, the Task Force has designated the term guideline-directed medical therapy (GDMT) to represent optimal medical therapy as defined by ACCF/AHA guideline recommended therapies (primarily Class I). This new term, GDMT, will be used herein and throughout all future guidelines.

Because the ACCF/AHA practice guidelines address patient populations (and healthcare providers) residing in North America, drugs that are not currently available in North America are discussed in the text without a specific COR. For studies performed in large numbers of subjects outside North America, each writing committee reviews the potential influence of different practice patterns and patient populations on the treatment effect and relevance to the ACCF/AHA target population to determine whether the findings should inform a specific recommendation.

The ACCF/AHA practice guidelines are intended to assist healthcare providers in clinical decision making by describing a range of generally acceptable approaches to the diagnosis, management, and prevention of specific diseases or conditions. The guidelines attempt to define practices that are determined to be of “no benefit” or is associated with “harm” to the patient. In addition, in view of the increasing number of comparative effectiveness studies, comparator verbs and suggested phrases for writing recommendations for the comparative effectiveness of one treatment or strategy versus another have been added for COR I and IIa, LOE A or B only.

In an effort to maintain relevance at the point of care for practicing physicians, the Task Force continues to oversee an ongoing process improvement initiative. As a result, in response to pilot projects, several changes to these guidelines will be apparent, including limited narrative text, a focus on summary and evidence tables (with references linked to abstracts in PubMed), and more liberal use of summary and evidence tables (with references linked to abstracts in PubMed, and more liberal use of summary recommendation tables (with references that support LOE) to serve as a quick reference.

In April 2011 the Institute of Medicine released 2 reports: Finding What Works in Health Care: Standards for Systematic Reviews and Clinical Practice Guidelines We Can Trust.2,3 It is noteworthy that the ACCF/AHA guidelines are cited as being compliant with many of the proposed standards. A thorough review of these reports and of our current methodology is under way, with further enhancements anticipated.

The recommendations in this guideline are considered current until they are superseded by a focused update or the full-text guideline is revised. Guidelines are official policy of both the ACCF and AHA.

Alice K. Jacobs, MD, FACC, FAHA
Chair, ACCF/AHA Task Force on Practice Guidelines
1. Introduction

1.1. Methodology and Evidence Review
The recommendations listed in this document are, whenever possible, evidence based. An extensive evidence review was conducted through November 2010, as well as selected other references through August 2011. Searches were limited to studies, reviews, and other evidence conducted in human subjects and that were published in English. Key search words included but were not limited to the following: ad hoc angioplasty, angioplasty, balloon angioplasty, clinical trial, coronary stenting, delayed angioplasty, meta-analysis, percutaneous transluminal coronary angioplasty, randomized controlled trial, percutaneous coronary intervention (PCI) and angiography, angiography reduction, antiplatelet therapy, bare-metal stents (BMS), cardiac rehabilitation, chronic stable angina, complication, coronary bifurcation lesion, coronary calcified lesion, coronary chronic total occlusion, coronary ostial lesions, coronary stent (BMS and drug-eluting stents [DES]; and BMS versus DES), diabetes, distal embolization, distal protection, elderly, ethics, late stent thrombosis, medical therapy, myocardial infarction, mortality, multiple lesions, multivessel, myocardial infarction, non-ST-elevation myocardial infarction (NSTEMI), no-reflow, optical coherence tomography, proton pump inhibitor, return to work, same-day angioplasty and/or stenting, slow flow, stable ischemic heart disease (SIHD), staged angioplasty, STEMI, survival, and unstable angina (UA). Additional searches cross-referenced these topics with the following subtopics: anticoagulant therapy, contrast nephropathy, PCI-related vascular complications, unprotected left main PCI, multivessel coronary artery disease (CAD), adjunctive percutaneous interventional devices, percutaneous hemodynamic support devices, and secondary prevention. Additionally, the committee reviewed documents related to the subject matter previously published by the ACCF and AHA. References selected and published in this document are representative and not all-inclusive.

Because the executive summary contains only the recommendations, the reader is encouraged to consult the full-text guideline for additional detail on the recommendations and guidance on the care of the patient undergoing PCI.

1.2. Organization of the Writing Committee
The committee was composed of physicians with expertise in interventional cardiology, general cardiology, critical care cardiology, cardiothoracic surgery, clinical trials, and health services research. The committee included representatives from the ACCF, AHA, and SCAI.

1.3. Document Review and Approval
This document was reviewed by 2 official reviewers nominated by the ACCF, AHA, and SCAI, as well as 21 individual content reviewers (including members of the ACCF Interventional Scientific Council and ACCF Surgeons’ Scientific Council). All information on reviewers’ RWI was distributed to the writing committee and is published in this document (Appendix 2). This document was approved for publication by the governing bodies of the ACCF, AHA, and SCAI.

1.4. PCI Guideline Scope
The evolution of the PCI guideline reflects the growth of knowledge in the field and parallels the many advances and innovations in the field of interventional cardiology, including primary PCI, BMS and DES, intravascular ultrasound (IVUS) and physiologic assessments of stenosis, and newer antiplatelet and anticoagulant therapies. The 2011 iteration of the guideline continues this process, addressing ethical aspects of PCI, vascular access considerations, CAD revascularization including hybrid revascularization, revascularization before noncardiac surgery, optical coherence tomography, advanced hemodynamic support devices, no-reflow therapies, and vascular closure devices. Most of this document is organized according to “patient flow,” consisting of preprocedural considerations, procedural considerations, and postprocedural considerations. The focus of this guideline is the safe, appropriate, and efficacious performance of PCI. The risks of PCI must be balanced against the likelihood of improved survival, symptoms, or functional status. This is especially important in patients with SIHD.

In a major undertaking, the STEMI, PCI, and coronary artery bypass graft (CABG) surgery guidelines were written concurrently, with additional collaboration with the SIHD guideline writing committee, allowing greater collaboration between the different writing committees on topics such as PCI in STEMI and revascularization strategies in patients with CAD (including unprotected left main PCI, multivessel disease revascularization, and hybrid procedures).

In accordance with direction from the Task Force and feedback from readers, in this iteration of the guideline, the text has been shortened, with an emphasis on summary statements rather than detailed discussion of numerous individual trials. Online supplemental evidence and summary tables have been created to document the studies and data considered for new or changed guideline recommendations.

2. CAD Revascularization: Recommendations
Recommendations and text in this section are the result of extensive collaborative discussions between the PCI and CABG writing committees, as well as key members of the SIHD and UA/NSTEMI writing committees. Certain issues, such as older versus more contemporary studies, primary analyses versus subgroup analyses, and prospective versus post hoc analyses, have been carefully weighed in designating COR and LOE; they are addressed in the appropriate corresponding text. The goals of revascularization for patients with CAD are to 1) improve survival and/or 2) relieve symptoms. The following text contains recommendations for revascularization to improve survival and symptoms, and they are presented in Tables 2 and 3.

Revascularization recommendations in this section are predominantly based on studies of patients with symptomatic SIHD and should be interpreted in this context. As discussed later in this section, recommendations on the type of revascularization are, in general, applicable to patients with UA/NSTEMI. In some cases (eg, unprotected left main CAD), specific recommendations are made for patients with UA/NSTEMI or STEMI.
Table 2. Revascularization to Improve Survival Compared With Medical Therapy

<table>
<thead>
<tr>
<th>Anatomic Setting</th>
<th>COR</th>
<th>LOE</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>UPLM or complex CAD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CABG and PCI</td>
<td>I—Heart Team approach recommended</td>
<td>C</td>
<td>5–7</td>
</tr>
<tr>
<td>CABG and PCI</td>
<td>Ila—Calculation of STS and SYNTAX scores</td>
<td>B</td>
<td>7–14</td>
</tr>
<tr>
<td>UPLM*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CABG</td>
<td>I</td>
<td>B</td>
<td>15–21</td>
</tr>
<tr>
<td>PCI</td>
<td>Ila—For SHD when both of the following are present:</td>
<td>B</td>
<td>8, 10, 11, 22–40, 106</td>
</tr>
<tr>
<td></td>
<td>● Anatomic conditions associated with a low risk of PCI procedural complications and a high likelihood of good long-term outcome (eg, a low SYNTAX score of &lt;22, cellal or trunk left main CAD)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>● Clinical characteristics that predict a significantly increased risk of adverse surgical outcomes (eg, STS-predicted risk of operative mortality &gt;5%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ila—For UA/NSTEMI if not a CABG candidate</td>
<td>B</td>
<td>11, 27, 29–31, 36, 37, 39–41</td>
</tr>
<tr>
<td></td>
<td>Ila—For STEMI when distal coronary flow is TIMI flow grade &lt;3 and PCI can be performed more rapidly and safely than CABG</td>
<td>C</td>
<td>24, 42, 43</td>
</tr>
<tr>
<td></td>
<td>IIb—For SHD when both of the following are present:</td>
<td>B</td>
<td>8, 10, 11, 22–40, 44</td>
</tr>
<tr>
<td></td>
<td>● Anatomic conditions associated with a low to intermediate risk of PCI procedural complications and an intermediate to high likelihood of good long-term outcome (eg, low-intermediate SYNTAX score of &lt;3, bifurcation left main CAD)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>● Clinical characteristics that predict an increased risk of adverse surgical outcomes (eg, moderate-severe COPD, disability from prior stroke, or prior cardiac surgery; STS-predicted risk of operative mortality &gt;2%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>III: Harm—For SHD in patients (versus performing CABG) with unfavorable anatomy for PCI and who are good candidates for CABG</td>
<td>B</td>
<td>8, 10,11, 15–23</td>
</tr>
<tr>
<td>3-vessel disease with or without proximal LAD artery disease*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CABG</td>
<td>I</td>
<td>B</td>
<td>17, 21, 45–48</td>
</tr>
<tr>
<td></td>
<td>Ila—It is reasonable to choose CABG over PCI in patients with complex 3-vessel CAD (eg, SYNTAX score &gt;22) who are good candidates for CABG</td>
<td>B</td>
<td>23, 38, 48, 63, 64</td>
</tr>
<tr>
<td>PCI</td>
<td>IIb—Of uncertain benefit</td>
<td>B</td>
<td>17, 45, 48, 74</td>
</tr>
<tr>
<td>2-vessel disease with proximal LAD artery disease*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CABG</td>
<td>I</td>
<td>B</td>
<td>17, 21, 45–48</td>
</tr>
<tr>
<td>PCI</td>
<td>IIb—Of uncertain benefit</td>
<td>B</td>
<td>17, 45, 48, 74</td>
</tr>
<tr>
<td>2-vessel disease without proximal LAD artery disease*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CABG</td>
<td>Ila—With extensive ischemia</td>
<td>B</td>
<td>52–55</td>
</tr>
<tr>
<td></td>
<td>IIb—Of uncertain benefit without extensive ischemia</td>
<td>C</td>
<td>48</td>
</tr>
<tr>
<td>PCI</td>
<td>IIb—Of uncertain benefit</td>
<td>B</td>
<td>17, 45, 48, 74</td>
</tr>
<tr>
<td>1-vessel proximal LAD artery disease</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CABG</td>
<td>Ila—With LIMA for long-term benefit</td>
<td>B</td>
<td>21, 48, 61, 62</td>
</tr>
<tr>
<td></td>
<td>IIb—Of uncertain benefit</td>
<td>B</td>
<td>17, 45, 48, 74</td>
</tr>
<tr>
<td>1-vessel disease without proximal LAD artery involvement</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CABG</td>
<td>III: Harm</td>
<td>B</td>
<td>21, 45, 52, 53, 86–90</td>
</tr>
<tr>
<td>PCI</td>
<td>III: Harm</td>
<td>B</td>
<td>21, 45, 52, 53, 86–90</td>
</tr>
<tr>
<td>LV dysfunction</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CABG</td>
<td>IIa—EF 35% to 50%</td>
<td>B</td>
<td>21, 56–60</td>
</tr>
<tr>
<td>CABG</td>
<td>IIb—EF &lt;35% without significant left main CAD</td>
<td>B</td>
<td>21, 56–60, 75, 76</td>
</tr>
<tr>
<td>PCI</td>
<td>Insufficient data</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Survivors of sudden cardiac death with presumed ischemia-mediated VT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CABG</td>
<td>I</td>
<td>B</td>
<td>49–51</td>
</tr>
<tr>
<td>PCI</td>
<td>I</td>
<td>C</td>
<td>49</td>
</tr>
</tbody>
</table>

*In patients with multivessel disease who also have diabetes, it is reasonable to choose CABG (with LIMA) over PCI.\(^{54,66–73}\) (Class IIa; LOE: B).

CABG indicates coronary artery bypass graft; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; COR, class of recommendation; EF, ejection fraction; LAD, left anterior descending; LIMA, left internal mammary artery; LOE, level of evidence; LV, left ventricular; N/A, not applicable; PCI, percutaneous coronary intervention; SIHD, stable ischemic heart disease; STEMI, ST-elevation myocardial infarction; STS, Society of Thoracic Surgeons; SYNTAX, Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery; TIMI, Thrombolysis In Myocardial Infarction; UA/NSTEMI, unstable angina/non-ST-elevation myocardial infarction; UPLM, unprotected left main disease; and VT, ventricular tachycardia.
2.1. Heart Team Approach to Revascularization Decisions

**Class I**

1. A Heart Team approach to revascularization is recommended in patients with unprotected left main or complex CAD.5–7 (Level of Evidence: C)

**Class IIa**

1. Calculation of the Society of Thoracic Surgeons and SYNTAX (Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery) scores is reasonable in patients with unprotected left main and complex CAD.7–14 (Level of Evidence: B)

2.2. Revascularization to Improve Survival

**Left Main CAD Revascularization**

**Class I**

1. CABG to improve survival is recommended for patients with significant (≥50% diameter stenosis) left main coronary artery stenosis.15–21 (Level of Evidence: B)

**Class IIa**

1. PCI to improve survival is reasonable as an alternative to CABG in selected stable patients with significant (≥50% diameter stenosis) unprotected left main CAD with: 1) anatomic conditions associated with a low to intermediate risk of PCI procedural complications and an intermediate to high likelihood of good long-term outcome (eg, low-intermediate SYNTAX score of <33, bifurcation left main CAD); and 2) clinical characteristics that predict an increased risk of adverse surgical outcomes (eg, moderate-severe chronic obstructive pulmonary disease, disability from previous stroke, or previous cardiac surgery; Society of Thoracic Surgeons–predicted risk of operative mortality >2%).8,10,11,15–23 (Level of Evidence: B)

2. PCI to improve survival is reasonable in patients with UA/NSTEMI when an unprotected left main coronary artery is the culprit lesion and the patient is not a candidate for CABG.11,27,29–31,36,37,39–41 (Level of Evidence: B)

3. PCI to improve survival is reasonable in patients with acute STEMI when an unprotected left main coronary artery is the culprit lesion, distal coronary flow is less than TIMI (Thrombolysis In Myocardial Infarction) grade 3, and PCI can be performed more rapidly and safely than CABG.24,42,43 (Level of Evidence: C)

**Class IIb**

1. PCI to improve survival may be reasonable as an alternative to CABG in selected stable patients with significant (≥50% diameter stenosis) unprotected left main CAD with: 1) anatomic conditions associated with a low intermediate risk of PCI procedural complications and an intermediate to high likelihood of good long-term outcome (eg, low-intermediate SYNTAX score of <33, bifurcation left main CAD); and 2) clinical characteristics that predict an increased risk of adverse surgical outcomes (eg, moderate-severe chronic obstructive pulmonary disease, disability from previous stroke, or previous cardiac surgery; Society of Thoracic Surgeons–predicted risk of operative mortality >2%).8,10,11,15–23 (Level of Evidence: B)

Class III: HARM

1. PCI to improve survival should not be performed in stable patients with significant (≥50% diameter stenosis) unprotected left main CAD who have unfavorable anatomy for PCI and who are good candidates for CABG.8,10,11,15–23 (Level of Evidence: B)

---

**Table 3. Revascularization to Improve Symptoms With Significant Anatomic (≥50% Left Main or ≥70% Non–Left Main CAD) or Physiological (FFR <0.80) Coronary Artery Stenoses**

<table>
<thead>
<tr>
<th>Clinical Setting</th>
<th>COR</th>
<th>LOE</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥1 significant stenoses amenable to revascularization and unacceptable angina despite GDMT</td>
<td>I-CABG</td>
<td>A</td>
<td>74, 91–100</td>
</tr>
<tr>
<td>≥1 significant stenoses and unacceptable angina in whom GDMT cannot be implemented because of medication contraindications, adverse effects, or patient preferences</td>
<td>I-IIa-PCI</td>
<td>C</td>
<td>N/A</td>
</tr>
<tr>
<td>Previous CABG with ≥1 significant stenoses associated with ischemia and unacceptable angiogram despite GDMT</td>
<td>IIa-CABG</td>
<td>C</td>
<td>78, 81, 84</td>
</tr>
<tr>
<td>Complex 3-vessel CAD (eg, SYNTAX score 22) with or without involvement of the proximal LAD artery and a good candidate for CABG</td>
<td>IIa-CABG preferred over PCI</td>
<td>B</td>
<td>23, 38, 48, 63, 64</td>
</tr>
<tr>
<td>Viable ischemic myocardium that is perfused by coronary arteries that are not amenable to grafting</td>
<td>IIb-TMR as an adjunct to CABG</td>
<td>B</td>
<td>101–105</td>
</tr>
<tr>
<td>No anatomic or physiologic criteria for revascularization</td>
<td>III: Harm-CABG</td>
<td>C</td>
<td>N/A</td>
</tr>
</tbody>
</table>

*GDMT indicates guideline-directed medical therapy; LOE, level of evidence; N/A, not applicable; PCI, percutaneous coronary intervention; SYNTAX, Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery; and TMR, transmyocardial laser revascularization.*
Non–Left Main CAD Revascularization

Class I
1. CABG to improve survival is beneficial in patients with significant (>70% diameter) stenoses in 3 major coronary arteries (with or without involvement of the proximal left anterior descending [LAD]) or in the proximal LAD plus 1 other major coronary artery.17,21,45–48 (Level of Evidence: B)
2. CABG or PCI to improve survival is beneficial in survivors of sudden cardiac death with presumed ischemia-mediated ventricular tachycardia caused by significant (>70% diameter) stenosis in a major coronary artery. (CABG Level of Evidence: B)49–51; PCI Level of Evidence: C49)

Class IIa
1. CABG to improve survival is reasonable in patients with significant (>70% diameter) stenoses in 2 major coronary arteries with severe or extensive myocardial ischemia (eg, high-risk criteria on stress testing, abnormal intracoronary hemodynamic evaluation, or >20% perfusion defect by myocardial perfusion stress imaging) or target vessels supplying a large area of viable myocardium.52–55 (Level of Evidence: B)
2. CABG to improve survival is reasonable in patients with mild-moderate left ventricular systolic dysfunction (ejection fraction 35% to 50%) and significant (>70% diameter stenosis) multivessel CAD or proximal LAD coronary artery stenosis, when viable myocardium is present in the region of intended revascularization.21,56–60 (Level of Evidence: B)
3. CABG with a left internal mammary artery graft to improve survival is reasonable in patients with significant (>70% diameter) stenosis in the proximal LAD artery and evidence of extensive ischemia.21,48,61,62 (Level of Evidence: B)
4. It is reasonable to choose CABG over PCI to improve survival in patients with complex 3-vessel CAD (eg, SYNTAX score >22) with or without involvement of the proximal LAD artery who are good candidates for CABG.23,38,48,63,64 (Level of Evidence: B)
5. CABG is probably recommended in preference to PCI to improve survival in patients with multivessel CAD and diabetes mellitus, particularly if a left internal mammary artery graft can be anastomosed to the LAD artery.54,66–73 (Level of Evidence: B)

Class IIb
1. The usefulness of CABG to improve survival is uncertain in patients with significant (>70%) stenoses in 2 major coronary arteries not involving the proximal LAD artery and without extensive ischemia.48 (Level of Evidence: C)
2. The usefulness of PCI to improve survival is uncertain in patients with 2- or 3-vessel CAD (with or without involvement of the proximal LAD artery) or 1-vessel proximal LAD disease.17,45,48,74 (Level of Evidence: B)
3. CABG might be considered with the primary or sole intent of improving survival in patients with SIHD with severe left ventricular systolic dysfunction (ejection fraction <35%) whether or not viable myocardium is present.21,56–60,75,76 (Level of Evidence: B)
4. The usefulness of CABG or PCI to improve survival is uncertain in patients with previous CABG and extensive anterior wall ischemia on noninvasive testing.77–85 (Level of Evidence: B)

Class III: HARM
1. CABG or PCI should not be performed with the primary or sole intent to improve survival in patients with SIHD with 1 or more coronary stenoses that are not anatomically or functionally significant (eg, <70% diameter non–left main coronary artery stenosis, fractional flow reserve >0.80, no or only mild ischemia on noninvasive testing), involve only the left circumflex or right coronary artery, or subtend only a small area of viable myocardium.21,45,52,86–90 (Level of Evidence: B)

2.3. Revascularization to Improve Symptoms

Class I
1. CABG or PCI to improve symptoms is beneficial in patients with 1 or more significant (>70% diameter) coronary artery stenoses amenable to revascularization and unacceptable angina despite GDMT.74,91–100 (Level of Evidence: A)

Class IIa
1. CABG or PCI to improve symptoms is reasonable in patients with 1 or more significant (>70% diameter) coronary artery stenoses and unacceptable angina for whom GDMT cannot be implemented because of medication contraindications, adverse effects, or patient preferences. (Level of Evidence: C)
2. PCI to improve symptoms is reasonable in patients with previous CABG, 1 or more significant (>70% diameter) coronary artery stenoses associated with ischemia, and unacceptable angina despite GDMT.78,81,84 (Level of Evidence: C)
3. It is reasonable to choose CABG over PCI to improve symptoms in patients with complex 3-vessel CAD (eg, SYNTAX score >22), with or without involvement of the proximal LAD artery who are good candidates for CABG.23,38,48,63,64 (Level of Evidence: B)

Class IIb
1. CABG to improve symptoms might be reasonable for patients with previous CABG, 1 or more significant (>70% diameter) coronary artery stenoses not amenable to PCI, and unacceptable angina despite GDMT.85 (Level of Evidence: C)
2. Transmyocardial laser revascularization performed as an adjunct to CABG to improve symptoms may be reasonable in patients with viable ischemic myocardium that is perfused by arteries that are not amenable to grafting.101–105 (Level of Evidence: B)
Class III: HARM
1. CABG or PCI to improve symptoms should not be performed in patients who do not meet anatomic (>50% left main or >70% non–left main stenosis) or physiological (eg, abnormal fractional flow reserve) criteria for revascularization. (Level of Evidence: C)

2.4. Clinical Factors That May Influence the Choice of Revascularization

2.4.1. Dual Antiplatelet Therapy Compliance and Stent Thrombosis

Class III: HARM
1. PCI with coronary stenting (BMS or DES) should not be performed if the patient is not likely to be able to tolerate and comply with dual antiplatelet therapy (DAPT) for the appropriate duration of treatment based on the type of stent implanted.107–110 (Level of Evidence: B)

2.5. Hybrid Coronary Revascularization

Class IIa
1. Hybrid coronary revascularization (defined as the planned combination of left internal mammary artery-to-LAD artery grafting and PCI of ≥1 non-LAD coronary arteries) is reasonable in patients with 1 or more of the following111–117 (Level of Evidence: B):
   a. Limitations to traditional CABG, such as heavily calcified proximal aorta or poor target vessels for CABG (but amenable to PCI);
   b. Lack of suitable graft conduits;
   c. Unfavorable LAD artery or PCI (ie, excessive vessel tortuosity or chronic total occlusion).

   Class IIb
1. Hybrid coronary revascularization (defined as the planned combination of left internal mammary artery-to-LAD artery grafting and PCI of ≥1 non-LAD coronary arteries) may be reasonable as an alternative to multivessel PCI or CABG in an attempt to improve the overall risk-benefit ratio of the procedures. (Level of Evidence: C)

3. Preprocedural Considerations: Recommendations

Table 4 contains recommendations for preprocedural considerations and interventions in patients undergoing PCI.

3.1. Radiation Safety

Class I
1. Cardiac catheterization laboratories should routinely record relevant available patient procedural
radiation dose data (eg, total air kerma at the international reference point \(K_{A,r}\), air kerma air product \(P_{KAA}\), fluoroscopy time, number of cine images), and should define thresholds with corresponding follow-up protocols for patients who receive a high procedural radiation dose. (Level of Evidence: C)

3.2. Contrast-Induced Acute Kidney Injury

Class I
1. Patients should be assessed for risk of contrast-induced acute kidney injury before PCI.\(^{118,119}\) (Level of Evidence: C)
2. Patients undergoing cardiac catheterization with contrast media should receive adequate preparatory hydration.\(^{120–123}\) (Level of Evidence: B)
3. In patients with CKD (creatinine clearance <60 mL/min), the volume of contrast media should be minimized.\(^{124–126}\) (Level of Evidence: B)

Class III: NO BENEFIT
1. Administration of N-acetyl-L-cysteine is not useful for the prevention of contrast-induced acute kidney injury.\(^{127–131}\) (Level of Evidence: A)

3.3. Anaphylactoid Reactions

Class I
1. Patients with prior evidence of an anaphylactoid reaction to contrast media should receive appropriate steroid and antihistamine prophylaxis before repeat contrast administration.\(^{132–135}\) (Level of Evidence: B)

Class III: NO BENEFIT
1. In patients with a prior history of allergic reactions to shellfish or seafood, anaphylactoid prophylaxis for contrast reaction is not beneficial.\(^{136–138}\) (Level of Evidence: C)

3.4. Statin Treatment

Class IIa
1. Administration of a high-dose statin is reasonable before PCI to reduce the risk of periprocedural myocardial infarction. (Level of Evidence: A for statin-naïve patients; Level of Evidence: B for those on chronic statin therapy)

3.5. Bleeding Risk

Class I
1. All patients should be evaluated for risk of bleeding before PCI. (Level of Evidence: C)

3.6. PCI in Hospitals Without On-Site Surgical Backup

Class IIa
1. Primary PCI is reasonable in hospitals without on-site cardiac surgery, provided that appropriate planning for program development has been accomplished.\(^{155,156}\) (Level of Evidence: B)

Class IIb
1. Elective PCI might be considered in hospitals without on-site cardiac surgery, provided that appropriate planning for program development has been accomplished and rigorous clinical and angiographic criteria are used for proper patient selection.\(^{156–158}\) (Level of Evidence: B)

Class III: HARM
1. Primary or elective PCI should not be performed in hospitals without on-site cardiac surgery capabilities without a proven plan for rapid transport to a cardiac surgery operating room in a nearby hospital or without appropriate hemodynamic support capability for transfer. (Level of Evidence: C)

4. Procedural Considerations: Recommendations

4.1. Vascular Access

Class IIa
1. The use of radial artery access can be useful to decrease access site complications.\(^{159–167}\) (Level of Evidence: A)

4.2. PCI in Specific Clinical Situations

4.2.1. Unstable Angina/Non–ST-Elevation Myocardial Infarction

Class I
1. An early invasive strategy (ie, diagnostic angiography with intent to perform revascularization) is indicated in UA/NSTEMI patients who have refractory angina or hemodynamic or electrical instability (without serious comorbidities or contraindications to such procedures).\(^{168–170}\) (Level of Evidence: B)
2. An early invasive strategy (ie, diagnostic angiography with intent to perform revascularization) is indicated in initially stabilized UA/NSTEMI patients (without serious comorbidities or contraindications to such procedures) who have an elevated risk for clinical events.\(^{169–172}\) (Level of Evidence: A)
3. The selection of PCI or CABG as the means of revascularization in the patient with acute coronary syndrome (ACS) should generally be based on the same considerations as those without ACS.\(^{165,170,173,174}\) (Level of Evidence: B)

Class III: NO BENEFIT
1. An early invasive strategy (ie, diagnostic angiography with intent to perform revascularization) is not recommended in patients with extensive comorbidities (eg, liver or pulmonary failure, cancer) in whom (Level of Evidence: C)
a. The risks of revascularization and comorbid conditions are likely to outweigh the benefits of revascularization,
b. There is a low likelihood of ACS despite acute chest pain, or
c. Consent to revascularization will not be granted regardless of the findings.

4.2.2. ST-Elevation Myocardial Infarction

Table 5 contains indications for coronary angiography in STEMI.

4.2.2.1. Coronary Angiography Strategies in STEMI

Class I

1. A strategy of immediate coronary angiography with intent to perform PCI (or emergency CABG) in patients with STEMI is recommended for:
   a. Patients who are candidates for primary PCI.\textsuperscript{155,175–178} (Level of Evidence: A)
   b. Patients with severe heart failure or cardiogenic shock who are suitable candidates for revascularization.\textsuperscript{179,180} (Level of Evidence: B)

Class IIa

1. A strategy of immediate coronary angiography (or transfer for immediate coronary angiography) with intent to perform PCI is reasonable for patients with STEMI, a moderate to large area of myocardium at risk, and evidence of failed fibrinolysis.\textsuperscript{181,182} (Level of Evidence: B)

2. A strategy of coronary angiography (or transfer for coronary angiography) 3 to 24 hours after initiating fibrinolytic therapy with intent to perform PCI is reasonable for hemodynamically stable patients with STEMI and evidence of successful fibrinolysis when angiography and revascularization can be performed as soon as logistically feasible in this time frame.\textsuperscript{183–187} (Level of Evidence: B)

Class IIb

1. A strategy of coronary angiography performed before hospital discharge might be reasonable in stable patients with STEMI who did not undergo cardiac catheterization within 24 hours of STEMI onset. (Level of Evidence: C)

Class III: NO BENEFIT

1. A strategy of coronary angiography with intent to perform PCI is not recommended in patients with STEMI in whom the risks of revascularization are likely to outweigh the benefits or when the patient or designee does not want invasive care. (Level of Evidence: C)

4.2.2.2. Primary PCI of the Infarct Artery

Class I

1. Primary PCI should be performed in patients within 12 hours of onset of STEMI.\textsuperscript{172–178} (Level of Evidence: A)

2. Primary PCI should be performed in patients with STEMI presenting to a hospital with PCI capability within 90 minutes of first medical contact as a systems goal.\textsuperscript{188,189} (Level of Evidence: B)

3. Primary PCI should be performed in patients with STEMI presenting to a hospital without PCI capability within 120 minutes of first medical contact as a systems goal.\textsuperscript{190–192} (Level of Evidence: B)

4. Primary PCI should be performed in patients with STEMI who develop severe heart failure or cardiogenic shock and are suitable candidates for revascularization as soon as possible, irrespective of time delay.\textsuperscript{179,180} (Level of Evidence: B)

5. Primary PCI should be performed as soon as possible in patients with STEMI and contraindications to fibrinolytic therapy with ischemic symptoms for less than 12 hours.\textsuperscript{193,194} (Level of Evidence: B)

Class IIa

1. Primary PCI is reasonable in patients with STEMI if there is clinical and/or electrocardiographic evidence of ongoing ischemia between 12 and 24 hours after symptom onset.\textsuperscript{195–197} (Level of Evidence: B)
Table 6. Indications for PCI in STEMI

<table>
<thead>
<tr>
<th>Indications</th>
<th>COR</th>
<th>LOE</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary PCI</strong>[a]</td>
<td>I</td>
<td>A</td>
<td>175–178</td>
</tr>
<tr>
<td>STEMI symptoms within 12 h</td>
<td>I</td>
<td>B</td>
<td>179, 180</td>
</tr>
<tr>
<td>Severe heart failure or cardiogenic shock</td>
<td>I</td>
<td>B</td>
<td>193, 194</td>
</tr>
<tr>
<td>Contraindications to fibrinolytic therapy with ischemic symptoms &lt;12 h</td>
<td>Iib</td>
<td>B</td>
<td>N/A</td>
</tr>
<tr>
<td>Clinical and/or electrocardiographic evidence of ongoing ischemia between 12 and 24 h after symptom onset</td>
<td>Iib</td>
<td>C</td>
<td>N/A</td>
</tr>
<tr>
<td>Asymptomatic patients presenting between 12 and 24 h after symptom onset and higher risk</td>
<td>III: Harm</td>
<td>B</td>
<td>198–202</td>
</tr>
<tr>
<td>Noninfarct artery PCI at the time of primary PCI in patients without hemodynamic compromise</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Delayed or elective PCI in patients with STEMI</strong></td>
<td>Iia</td>
<td>B</td>
<td>181, 182</td>
</tr>
<tr>
<td>Clinical evidence for fibrinolytic failure or infarct artery reocclusion</td>
<td>Iia</td>
<td>B</td>
<td>186, 187</td>
</tr>
<tr>
<td>Patent infarct artery 3 to 24 h after fibrinolytic therapy</td>
<td>Iia</td>
<td>B</td>
<td>203, 204</td>
</tr>
<tr>
<td>Ischemia on noninvasive testing</td>
<td>Iib</td>
<td>B</td>
<td>205–209</td>
</tr>
<tr>
<td>Hemodynamically significant stenosis in a patent infarct artery &gt;24 h after STEMI</td>
<td>Iib: No Benefit</td>
<td>B</td>
<td>210–212</td>
</tr>
<tr>
<td>Totally occluded infarct artery &gt;24 h after STEMI in a hemodynamically stable asymptomatic patient without evidence of severe ischemia</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*a* Systems goal of performing primary PCI within 90 min of first medical contact when the patient presents to a hospital with PCI capability,[188,189] (*Class I; LOE: B*) and within 120 min when the patient presents to a hospital without PCI capability.[190–192] (*Class I; LOE: B*).

**COR** indicates class of recommendation; **LOE**, level of evidence; **N/A**, not applicable; **PCI**, percutaneous coronary intervention; and **STEMI**, ST-elevation myocardial infarction.

4.2.3. Cardiogenic Shock

**Class I**

1. PCI is recommended for patients with acute myocardial infarction who develop cardiogenic shock and are suitable candidates.[190–215] (*Level of Evidence: B*)

2. A hemodynamic support device is recommended for patients with cardiogenic shock after STEMI who do not quickly stabilize with pharmacological therapy.[190,216–219] (*Level of Evidence: B*)

4.2.4. Revascularization Before Noncardiac Surgery

**Class IIa**

1. For patients who require PCI and are scheduled for elective noncardiac surgery in the subsequent 12 months, a strategy of balloon angioplasty, or BMS implantation followed by 4 to 6 weeks of DAPT, is reasonable.[220–226] (*Level of Evidence: B*)

2. For patients with DES who must undergo urgent surgical procedures that mandate the discontinuation of DAPT, it is reasonable to continue aspirin if possible and restart the P2Y12 inhibitor as soon as possible in the immediate postoperative period.[222,227] (*Level of Evidence: C*)

**Class III: HARM**

1. Routine prophylactic coronary revascularization should not be performed in patients with stable CAD before noncardiac surgery.[228,229] (*Level of Evidence: B*)

2. Elective noncardiac surgery should not be performed in the 4 to 6 weeks after balloon angioplasty or BMS implantation or the 12 months after DES implantation in patients in whom the P2Y12 inhibitor will need to be discontinued perioperatively.[107,225,230,231] (*Level of Evidence: B*)

4.2.2.3. Delayed or Elective PCI in Patients With STEMI

**Class IIb**

1. PCI is reasonable in patients with STEMI and clinical evidence for fibrinolytic failure or infarct artery reocclusion.[181,182] (*Level of Evidence: B*)

2. PCI is reasonable in patients with STEMI and a patent infarct artery 3 to 24 hours after fibrinolytic therapy.[186,187] (*Level of Evidence: B*)

3. PCI is reasonable in patients with STEMI who demonstrate ischemia on noninvasive testing.[203,204] (*Level of Evidence: B*)

**Class IIb**

1. PCI of a hemodynamically significant stenosis in a patent infarct artery greater than 24 hours after STEMI may be considered as part of an invasive strategy.[205–209] (*Level of Evidence: B*)

**Class III: NO BENEFIT**

1. PCI of a totally occluded infarct artery greater than 24 hours after STEMI should not be performed in asymptomatic patients with 1- or 2-vessel disease if patients are hemodynamically and electrically stable and do not have evidence of severe ischemia.[210–212] (*Level of Evidence: B*)
4.3. Coronary Stents
Class I
1. Before implantation of DES, the interventional cardiologist should discuss with the patient the need for and duration of DAPT and the ability of the patient to comply with and tolerate DAPT.232 (Level of Evidence: C)
2. DES are useful as an alternative to BMS to reduce the risk of restenosis in cases in which the risk of restenosis is increased and the patient is likely to be able to tolerate and comply with prolonged DAPT (Level of Evidence: A for elective PCI233–237; Level of Evidence: C for UA/NSTEMI235; Level of Evidence: A for STEMI235,236,238–240).
3. Balloon angioplasty or BMS should be used in patients with high bleeding risk, inability to comply with 12 months of DAPT, or anticipated invasive or surgical procedures within the next 12 months, during which time DAPT may be interrupted.107,241–243 (Level of Evidence: B)

Class III: HARM
1. PCI with coronary stenting should not be performed if the patient is not likely to be able to tolerant and comply with DAPT or this cannot be determined before stent implantation.107,241–243 (Level of Evidence: B)

4.4. Adjunctive Diagnostic Devices
4.4.1. Fractional Flow Reserve

Class IIa
1. Fractional flow reserve is reasonable to assess angiographic intermediate coronary lesions (50% to 70% diameter stenosis) and can be useful for guiding revascularization decisions in patients with SIHD.89,244–247 (Level of Evidence: A)

Class IIb
1. IVUS is reasonable for the assessment of angiographically indeterminant left main CAD.248–250 (Level of Evidence: B)
2. IVUS and coronary angiography are reasonable 4 to 6 weeks and 1 year after cardiac transplantation to exclude donor CAD, detect rapidly progressive cardiac allograft vasculopathy, and provide prognostic information.251–253 (Level of Evidence: B)
3. IVUS is reasonable to determine the mechanism of stent restenosis.254 (Level of Evidence: C)

Class III: NO BENEFIT
1. IVUS for routine lesion assessment is not recommended when revascularization with PCI or CABG is not being contemplated. (Level of Evidence: C)

4.5. Adjunctive Therapeutic Devices
4.5.1. Coronary Atherectomy

Class IIa
1. Rotational atherectomy should not be performed routinely for de novo lesions or in-stent restenosis.266 (Level of Evidence: A)

Class IIb
1. Aspiration thrombectomy is reasonable for patients undergoing primary PCI.264–266 (Level of Evidence: B)
### 4.5.3. Laser Angioplasty

**Class IIb**

1. Laser angioplasty might be considered for fibrotic or moderately calcified lesions that cannot be crossed or dilated with conventional balloon angioplasty.\(^{267}\) *(Level of Evidence: C)*

**Class III: NO BENEFIT**

1. Laser angioplasty should not be used routinely during PCI.\(^{260,269,270}\) *(Level of Evidence: A)*

### 4.5.4. Cutting Balloon Angioplasty

**Class IIb**

1. Cutting balloon angioplasty might be considered to avoid slippage-induced coronary artery trauma during PCI for in-stent restenosis or ostial lesions in side branches.\(^{269}\) *(Level of Evidence: C)*

**Class III: NO BENEFIT**

1. Cutting balloon angioplasty should not be performed routinely during PCI.\(^{260,269,270}\) *(Level of Evidence: A)*

### 4.5.5. Embolic Protection Devices

**Class I**

1. Embolic protection devices should be used during saphenous vein graft PCI when technically feasible.\(^{271–274}\) *(Level of Evidence: B)*

### 4.6. Percutaneous Hemodynamic Support Devices

Table 7 contains recommendations for antiplatelet and antithrombin pharmacotherapy at the time of PCI.

**Table 7. Recommendations for Antiplatelet and Antithrombin Pharmacotherapy at the Time of PCI**

<table>
<thead>
<tr>
<th>ORG</th>
<th>COR</th>
<th>LOE</th>
<th>References</th>
<th>Relevant Caveats/Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Oral antiplatelet agents</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ASA</td>
<td>I</td>
<td>B</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>P2Y(_{12}) Inhibitors</td>
<td>I</td>
<td>A</td>
<td>279–283</td>
<td>A loading dose of a P2Y(_{12}) inhibitor should be given to patients undergoing PCI with stenting.</td>
</tr>
<tr>
<td>Clopidogrel</td>
<td>I</td>
<td>B</td>
<td>279–281</td>
<td></td>
</tr>
<tr>
<td>Prasugrel</td>
<td>I</td>
<td>B</td>
<td>282</td>
<td></td>
</tr>
<tr>
<td>Ticagrelor</td>
<td>I</td>
<td>B</td>
<td>283</td>
<td></td>
</tr>
<tr>
<td><strong>GP Ibb/Illa inhibitors (abciximab, double-bolus eptifibatide, high-bolus dose tirofiban)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No clopidogrel pretreatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>STEMI: Ila</td>
<td>B</td>
<td>A</td>
<td>292–298</td>
<td></td>
</tr>
<tr>
<td>UA/NSTEMI: Ila</td>
<td>B</td>
<td>A</td>
<td>321–326</td>
<td></td>
</tr>
<tr>
<td>SIHD: Ila</td>
<td>B</td>
<td>327–329</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clopidogrel pretreatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>STEMI: Ila</td>
<td>B</td>
<td>C</td>
<td>292–298</td>
<td></td>
</tr>
<tr>
<td>UA/NSTEMI: Ila</td>
<td>B</td>
<td>324, 327</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SIHD: Ila</td>
<td>B</td>
<td>327, 330–332</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Antithrombin agents</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>UFH</td>
<td>I</td>
<td>C</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Bivalirudin</td>
<td>I</td>
<td>B</td>
<td>333–342</td>
<td></td>
</tr>
<tr>
<td>Enoxaparin</td>
<td>Ibb</td>
<td>B</td>
<td>343–347</td>
<td></td>
</tr>
<tr>
<td><strong>Anti-Xa inhibitors</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fondaparinux</td>
<td>III: Harm</td>
<td>C</td>
<td>348, 349</td>
<td></td>
</tr>
</tbody>
</table>

---

ACT indicates activated clotting time; COR, class of recommendation; CVA, cerebrovascular accident; FDA, U.S. Food and Drug Administration; GP, glycoprotein; GPI, glycoprotein IIb/IIIa inhibitor; IC, intracoronary; IV, intravenous; LOE, level of evidence; MI, myocardial infarction; N/A, not applicable; PCI, percutaneous coronary intervention; SC, subcutaneous; SIHD, stable ischemic heart disease; STEMI, ST-elevation myocardial infarction; TIA, transient ischemic attack; UA/NSTEMI, unstable angina/non-ST-elevation myocardial infarction; and UFH, unfractionated heparin.
Class IIb

1. Elective insertion of an appropriate hemodynamic support device as an adjunct to PCI may be reasonable in carefully selected high-risk patients. \(\text{(Level of Evidence: C)}\)

4.6.1. Oral Antiplatelet Therapy

Class I

1. Patients already taking daily aspirin therapy should take 81 mg to 325 mg before PCI. \(\text{(Level of Evidence: B)}\)

2. Patients not on aspirin therapy should be given nonenteric aspirin 325 mg before PCI. \(\text{(Level of Evidence: B)}\)

3. After PCI, use of aspirin should be continued indefinitely. \(\text{(Level of Evidence: A)}\)

4. A loading dose of a P2Y\(_{12}\) receptor inhibitor should be given to patients undergoing PCI with stenting. \(\text{(Level of Evidence: A)}\)

   a. Clopidogrel 600 mg (ACS and non-ACS patients). \(\text{(Level of Evidence: B)}\)
   
   b. Prasugrel 60 mg (ACS patients). \(\text{(Level of Evidence: B)}\)
   
   c. Ticagrelor 180 mg (ACS patients). \(\text{(Level of Evidence: B)}\)

5. The loading dose of clopidogrel for patients undergoing PCI after fibrinolytic therapy should be 300 mg within 24 hours and 600 mg more than 24 hours after receiving fibrinolytic therapy. \(\text{(Level of Evidence: C)}\)

6. Patients should be counseled on the need for and risks of DAPT before placement of intracoronary stents, especially DES, and alternative therapies should be pursued if patients are unwilling or unable to comply with the recommended duration of DAPT. \(\text{(Level of Evidence: C)}\)

7. The duration of P2Y\(_{12}\) inhibitor therapy after stent implantation should generally be as follows:
   
   a. In patients receiving a stent (BMS or DES) during PCI for ACS, P2Y\(_{12}\) inhibitor therapy should be given for at least 12 months. Options include clopidogrel 75 mg daily, \(\text{(Level of Evidence: B)}\) prasugrel 10 mg daily, \(\text{(Level of Evidence: B)}\) and ticagrelor 90 mg twice daily. \(\text{(Level of Evidence: B)}\)

   b. In patients receiving DES for a non-ACS indication, clopidogrel 75 mg daily should be given for at least 12 months if patients are not at high risk of bleeding. \(\text{(Level of Evidence: B)}\)

   c. In patients receiving BMS for a non-ACS indication, clopidogrel should be given for a minimum of 1 month and ideally up to 12 months (unless the patient is at increased risk of bleeding; then it should be given for a minimum of 2 weeks). \(\text{(Level of Evidence: B)}\)

Class IIa

1. After PCI, it is reasonable to use aspirin 81 mg per day in preference to higher maintenance doses. \(\text{(Level of Evidence: B)}\)

2. If the risk of morbidity from bleeding outweighs the anticipated benefit afforded by a recommended duration of P2Y\(_{12}\) inhibitor therapy after stent implantation, earlier discontinuation (eg, <12 months) of P2Y\(_{12}\) inhibitor therapy is reasonable. \(\text{(Level of Evidence: C)}\)

Class IIb

1. Continuation of DAPT beyond 12 months may be considered in patients undergoing DES implantation. \(\text{(Level of Evidence: C)}\)

Class III: HARM

1. Prasugrel should not be administered to patients with a prior history of stroke or transient ischemic attack. \(\text{(Level of Evidence: B)}\)

4.6.2. Intravenous Antiplatelet Therapy

STEMI

Class IIa

1. In patients undergoing primary PCI treated with unfractionated heparin (UFH), it is reasonable to administer a glycoprotein (GP) IIb/IIIa inhibitor (abciximab, double-bolus epifibatide, or high-bolus dose tirofiban), whether or not patients were pretreated with clopidogrel. \(\text{(For GP IIb/IIIa inhibitor administration in patients not pretreated with clopidogrel, Level of Evidence: A; for GP IIb/IIIa inhibitor administration in patients pretreated with clopidogrel, Level of Evidence: C)}\)

Class IIb

1. In patients undergoing primary PCI with abciximab, it may be reasonable to administer intracoronary abciximab. \(\text{(Level of Evidence: B)}\)

Class III: NO BENEFIT

1. Routine precatheterization laboratory (eg, ambulance or emergency room) administration of GP IIb/IIIa inhibitors as part of an upstream strategy for patients with STEMI undergoing PCI is not beneficial. \(\text{(Level of Evidence: B)}\)

UA/NSTEMI

Class I

1. In UA/NSTEMI patients with high-risk features (eg, elevated troponin level) not treated with bivalirudin and not adequately pretreated with clopidogrel, it is useful at the time of PCI to administer a GP IIb/IIIa inhibitor (abciximab, double-bolus epifibatide, or high-bolus dose tirofiban) in patients treated with UFH. \(\text{(Level of Evidence: A)}\)

Class IIa

1. In UA/NSTEMI patients with high-risk features (eg, elevated troponin level) treated with UFH and adequately pretreated with clopidogrel, it is reasonable at the time of PCI to administer a GP IIb/IIIa inhibitor (abciximab, double-bolus epifibatide, or high-bolus dose tirofiban). \(\text{(Level of Evidence: B)}\)
Class IIa
1. In patients undergoing elective PCI treated with UFH and not pretreated with clopidogrel, it is reasonable to administer a GP IIb/IIIa inhibitor (abciximab, double-bolus eptifibatide, or high-bolus dose tirofiban).327–329 (Level of Evidence: B)

Class IIb
1. In patients undergoing elective PCI with stent implantation treated with UFH and adequately pretreated with clopidogrel, it might be reasonable to administer a GP IIb/IIIa inhibitor (abciximab, double-bolus eptifibatide, or high-bolus dose tirofiban).327,330–332 (Level of Evidence: B)

4.6.3. Anticoagulant Therapy
4.6.3.1. Use of Parenteral Anticoagulants During PCI
Class I
1. An anticoagulant should be administered to patients undergoing PCI. (Level of Evidence: C)

Class III: HARM
1. UFH should not be given to patients already receiving therapeutic subcutaneous enoxaparin.346,354 (Level of Evidence: B)

4.6.3.2. Unfractionated Heparin
Class I
1. Administration of IV UFH is useful in patients undergoing PCI. (Level of Evidence: C)

Class III: NO BENEFIT
1. Platelet GP IIb/IIIa inhibitors are not beneficial as adjunctive therapy during saphenous vein graft PCI.232,286,378,379 (Level of Evidence: B)

Class III: HARM
1. PCI is not recommended for chronic saphenous vein graft occlusions.380–382 (Level of Evidence: C)

4.6.3.3. Enoxaparin
Class I
1. An additional dose of 0.3 mg/kg IV enoxaparin should be administered at the time of PCI to patients who have received fewer than 2 therapeutic subcutaneous doses (eg, 1 mg/kg) or received the last subcutaneous enoxaparin dose 8 to 12 hours before PCI.346,350–353 (Level of Evidence: B)

Class IIb
1. Performance of PCI with enoxaparin may be reasonable in patients either treated with “upstream” subcutaneous enoxaparin for UA/NSTEMI or who have not received prior antithrombin therapy and are administered IV enoxaparin at the time of PCI.343–347 (Level of Evidence: B)

Class III: HARM
1. UFH should not be given to patients already receiving therapeutic subcutaneous enoxaparin.346,354 (Level of Evidence: B)

4.6.3.4. Bivalirudin and Argatroban
Class I
1. For patients undergoing PCI, bivalirudin is useful as an anticoagulant with or without prior treatment with UFH.333–342 (Level of Evidence: B)

Class III: HARM
1. Fondaparinux should not be used as the sole anticoagulant to support PCI. An additional anticoagulant with anti-IIa activity should be administered because of the risk of catheter thrombosis.348,349 (Level of Evidence: C)

4.6.4. No-Reflow Pharmacological Therapies
Class IIa
1. Administration of an intracoronary vasodilator (adenosine, calcium channel blocker, or nitroprusside) is reasonable to treat PCI-related no-reflow that occurs during primary or elective PCI.357–372 (Level of Evidence: B)

4.7. PCI in Specific Anatomic Situations
4.7.1. Chronic Total Occlusions
Class IIa
1. PCI of a chronic total occlusion in patients with appropriate clinical indications and suitable anatomy is reasonable when performed by operators with appropriate expertise.373–377 (Level of Evidence: C)

Class III: HARM
1. PCI is not recommended for chronic saphenous vein graft occlusions.380–382 (Level of Evidence: C)

4.7.2. Saphenous Vein Grafts
Class I
1. Embolic protection devices should be used during saphenous vein graft PCI when technically feasible.271–274 (Level of Evidence: B)

Class III: NO BENEFIT
1. Platelet GP IIb/IIIa inhibitors are not beneficial as adjunctive therapy during saphenous vein graft PCI.232,286,378,379 (Level of Evidence: B)

Class III: HARM
1. PCI is not recommended for chronic saphenous vein graft occlusions.380–382 (Level of Evidence: C)

4.7.3. Bifurcation Lesions
Class I
1. Provisional side-branch stenting should be the initial approach in patients with bifurcation lesions when the side branch is not large and has only mild or moderate focal disease at the ostium.383–386 (Level of Evidence: A)

Class III: HARM
1. It is reasonable to use elective double stenting in patients with complex bifurcation morphology involving a large side branch where the risk of side-branch occlusion is high and the likelihood of successful side-branch reaccess is low.387–390 (Level of Evidence: B)

4.7.4. Aorto-Ostial Stenoses
Class I
1. IVUS is reasonable for the assessment of angiographically indeterminant left main CAD.391,392 (Level of Evidence: B)
<table>
<thead>
<tr>
<th>Recommendations</th>
<th>COR</th>
<th>LOE</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Aspirin</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>After PCI, use of aspirin should be continued indefinitely.</td>
<td>I</td>
<td>A</td>
<td>275–278</td>
</tr>
<tr>
<td>After PCI, it is reasonable to use aspirin 81 mg/d in preference to higher maintenance doses.</td>
<td>Ila</td>
<td>B</td>
<td>151, 288–291</td>
</tr>
<tr>
<td><strong>P2Y₁₂ inhibitors</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>In patients receiving a stent (BMS or DES) during PCI for ACS, P2Y₁₂ inhibitor therapy should be given for at least 12 mo. Options include clopidogrel 75 mg/d, prasugrel 10 mg/d, and ticagrelor 90 mg twice daily.</td>
<td>I</td>
<td>B</td>
<td>282, 283, 285</td>
</tr>
<tr>
<td>In patients receiving DES for a non-ACS indication, clopidogrel 75 mg/d should be given for at least 12 mo if patients are not at high risk of bleeding.</td>
<td>I</td>
<td>B</td>
<td>107, 232, 286</td>
</tr>
<tr>
<td>In patients receiving BMS for a non-ACS indication, clopidogrel should be given for a minimum of 1 mo and ideally up to 12 mo (unless the patient is at increased risk of bleeding; then it should be given for a minimum of 2 wk).</td>
<td>I</td>
<td>B</td>
<td>287</td>
</tr>
<tr>
<td>Patients should be counseled on the importance of compliance with DAPT and that therapy should not be discontinued before discussion with their cardiologist.</td>
<td>I</td>
<td>C</td>
<td>107</td>
</tr>
<tr>
<td>PPIs should be used in patients with a history of prior GI bleeding who require DAPT.</td>
<td>I</td>
<td>C</td>
<td>402</td>
</tr>
<tr>
<td>If the risk of morbidity from bleeding outweighs the anticipated benefit afforded by a recommended duration of P2Y₁₂ inhibitor therapy after stent implantation, earlier discontinuation (eg, &lt;12 mo) of P2Y₁₂ inhibitor therapy is reasonable.</td>
<td>Ila</td>
<td>C</td>
<td>N/A</td>
</tr>
<tr>
<td>Use of PPIs is reasonable in patients with an increased risk of GI bleeding (eg, advanced age, concomitant use of warfarin, steroids, NSAIDs, <em>Helicobacter pylori</em> infection) who require DAPT.</td>
<td>Ila</td>
<td>C</td>
<td>402</td>
</tr>
<tr>
<td>Continuation of clopidogrel, prasugrel, or ticagrelor beyond 12 mo may be considered in patients undergoing placement of DES.</td>
<td>Iib</td>
<td>C</td>
<td>282, 283</td>
</tr>
<tr>
<td>Routine use of a PPI is not recommended for patients at low risk of GI bleeding, who have much less potential to benefit from prophylactic therapy.</td>
<td>III: No Benefit</td>
<td>C</td>
<td>402</td>
</tr>
<tr>
<td><strong>Exercise testing</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>For patients entering a formal cardiac rehabilitation program after PCI, treadmill exercise testing is reasonable.</td>
<td>Ila</td>
<td>C</td>
<td>N/A</td>
</tr>
<tr>
<td>Routine periodic stress testing of asymptomatic patients after PCI without specific clinical indications should not be performed.</td>
<td>III: No Benefit</td>
<td>C</td>
<td>403</td>
</tr>
<tr>
<td><strong>Cardiac rehabilitation</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medically supervised exercise programs (cardiac rehabilitation) should be recommended to patients after PCI, particularly for patients at moderate to high risk for whom supervised exercise training is warranted.</td>
<td>I</td>
<td>A</td>
<td>404–412</td>
</tr>
<tr>
<td><strong>Secondary prevention (recommendations included from the 2011 AHA/ACCF Secondary Prevention and Risk Reduction Therapy Guideline)</strong>:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lipid management with lifestyle modification and lipid-lowering pharmacotherapy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lifestyle modification</td>
<td>I</td>
<td>B</td>
<td>414, 415</td>
</tr>
<tr>
<td>Statin therapy</td>
<td>I</td>
<td>A</td>
<td>414, 416–419, 419a</td>
</tr>
<tr>
<td>Statin therapy which lowers LDL cholesterol to &lt;100 mg/dL and achieves at least a 30% lowering of LDL cholesterol</td>
<td>I</td>
<td>C</td>
<td>414–419, 419a</td>
</tr>
<tr>
<td>Statin therapy which lowers LDL cholesterol to &lt;70 mg/dL in very high-risk* patients</td>
<td>Ila</td>
<td>C</td>
<td>416–418, 419a, 420–422</td>
</tr>
<tr>
<td>Blood pressure control (with a blood pressure goal of &lt;140/90 mm Hg)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lifestyle modification</td>
<td>I</td>
<td>B</td>
<td>423–427</td>
</tr>
<tr>
<td>Pharmacotherapy</td>
<td>I</td>
<td>A</td>
<td>423, 428, 429</td>
</tr>
<tr>
<td>Diabetes management (eg, lifestyle modification and pharmacotherapy) coordinated with the patient’s primary care physician and/or endocrinologist</td>
<td>I</td>
<td>C</td>
<td>N/A</td>
</tr>
<tr>
<td>Complete smoking cessation</td>
<td>I</td>
<td>A</td>
<td>430–433</td>
</tr>
</tbody>
</table>

*Presence of established cardiovascular disease plus 1) multiple major risk factors (especially diabetes), 2) severe and poorly controlled risk factors (especially continued cigarette smoking), 3) multiple risk factors of the metabolic syndrome (especially high triglycerides ≥200 mg/dL plus non-HDL-cholesterol ≥130 mg/dL with low HDL-cholesterol ≤40 mg/dL), and 4) acute coronary syndromes.

ACS indicates acute coronary syndromes; BMS, bare-metal stent(s); COR, class of recommendation; DAPT, dual antiplatelet therapy; DES, drug-eluting stent(s); GI, gastrointestinal; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LOE, level of evidence; N/A, not applicable; NSAID, nonsteroidal anti-inflammatory drug; PCI, percutaneous coronary intervention; and PPI, proton pump inhibitor.
2. Use of DES is reasonable when PCI is indicated in patients with an aorto-ostial stenosis.\(^{393,394}\) *(Level of Evidence: B)*

### 4.7.5. Calcified Lesions

**Class IIa**

1. Rotational atherectomy is reasonable for fibrotic or heavily calcified lesions that might not be crossed by a balloon catheter or adequately dilated before stent implantation.\(^{258,259,395}\) *(Level of Evidence: C)*

### 4.8. PCI in Specific Patient Populations

#### 4.8.1. Chronic Kidney Disease

**Class I**

In patients undergoing PCI, the glomerular filtration rate should be estimated and the dosage of renally cleared medications should be adjusted.\(^{147–149}\) *(Level of Evidence: B)*

### 4.9. Periprocedural Myocardial Infarction Assessment

**Class I**

1. In patients who have signs or symptoms suggestive of myocardial infarction during or after PCI or in asymptomatic patients with significant persistent angiographic complications (eg, large side-branch occlusion, flow-limiting dissection, no-reflow phenomenon, or coronary thrombosis), creatine kinase-MB and/or troponin I or T should be measured.\(^{147–149}\) *(Level of Evidence: C)*

**Class IIb**

1. Routine measurement of cardiac biomarkers (creatinine kinase-MB and/or troponin I or T) in all patients after PCI may be reasonable.\(^{147–149}\) *(Level of Evidence: C)*

### 4.10. Vascular Closure Devices

**Class I**

1. Patients considered for vascular closure devices should undergo a femoral angiogram to ensure their anatomic suitability for deployment.\(^{147–149}\) *(Level of Evidence: C)*

**Class IIa**

1. The use of vascular closure devices is reasonable for the purposes of achieving faster hemostasis and earlier ambulation compared with the use of manual compression.\(^{396–399}\) *(Level of Evidence: B)*

**Class III: NO BENEFIT**

1. The routine use of vascular closure devices is not recommended for the purpose of decreasing vascular complications, including bleeding.\(^{396–401}\) *(Level of Evidence: B)*

### 5. Postprocedural Considerations: Recommendations

Postprocedural considerations in patients undergoing PCI are discussed below and summarized in Table 8. Some recommendations and text regarding DAPT in Section 5.7.2 of the full-text guideline are intentionally repeated in this section for reader ease of use.

#### 5.1. Postprocedural Antiplatelet Therapy

**Class I**

1. After PCI, use of aspirin should be continued indefinitely.\(^{275–278}\) *(Level of Evidence: A)*

2. The duration of P2Y\(_{12}\) inhibitor therapy after stent implantation should generally be as follows:
   
   a. In patients receiving a stent (BMS or DES) during PCI for ACS, P2Y\(_{12}\) inhibitor therapy should be given for at least 12 months. Options include clopidogrel 75 mg daily,\(^{285}\) prasugrel 10 mg daily,\(^{282}\) and ticagrelor 90 mg twice daily.\(^{283}\) *(Level of Evidence: B)*
   
   b. In patients receiving DES for a non-ACS indication, clopidogrel 75 mg daily should be given for at least 12 months if the patient is not at high risk of bleeding.\(^{107,232,286}\) *(Level of Evidence: B)*
   
   c. In patients receiving BMS for a non-ACS indication, clopidogrel should be given for a minimum of 1 month and ideally up to 12 months (unless the patient is at increased risk of bleeding; then it should be given for a minimum of 2 weeks).\(^{287}\) *(Level of Evidence: B)*

**Class IIb**

1. Patients should be counseled on the importance of compliance with DAPT and that therapy should not be discontinued before discussion with their cardiologist.\(^{107}\) *(Level of Evidence: C)*

**Class IIa**

1. After PCI, it is reasonable to use aspirin 81 mg per day in preference to higher maintenance doses.\(^{151,288–291}\) *(Level of Evidence: B)*

2. If the risk of morbidity from bleeding outweighs the anticipated benefit afforded by a recommended duration of P2Y\(_{12}\) inhibitor therapy after stent implantation, earlier discontinuation (eg, <12 months) of P2Y\(_{12}\) inhibitor therapy is reasonable.\(^{151,288–291}\) *(Level of Evidence: C)*

**Class IIb**

1. Continuation of clopidogrel, prasugrel or ticagrelor beyond 12 months may be considered in patients undergoing placement of DES.\(^{282,283}\) *(Level of Evidence: C)*

#### 5.1.1. Proton Pump Inhibitors and Antiplatelet Therapy

**Class I**

1. Proton pump inhibitors should be used in patients with a history of prior gastrointestinal bleeding who require DAPT.\(^{402}\) *(Level of Evidence: C)*

**Class IIa**

1. Use of proton pump inhibitors is reasonable in patients with an increased risk of gastrointestinal bleeding (eg, advanced age, concomitant use of warfarin, steroids, nonsteroidal anti-inflammatory drugs, *Helicobacter pylori* infection) who require DAPT.\(^{402}\) *(Level of Evidence: C)*

**Class III: NO BENEFIT**

1. Routine use of a proton pump inhibitor is not recommended for patients at low risk of gastrointestinal bleeding, who have much less potential to benefit from prophylactic therapy.\(^{402}\) *(Level of Evidence: C)*
5.1.2. Clopidogrel Genetic Testing

Class IIb
1. Genetic testing might be considered to identify whether a patient at high risk for poor clinical outcomes is predisposed to inadequate platelet inhibition with clopidogrel.434 (Level of Evidence: C)
2. When a patient predisposed to inadequate platelet inhibition with clopidogrel is identified by genetic testing, treatment with an alternate P2Y12 inhibitor (eg, prasugrel or ticagrelor) might be considered.434 (Level of Evidence: C)

Class III: NO BENEFIT
1. The routine clinical use of genetic testing to screen patients treated with clopidogrel who are undergoing PCI is not recommended.434 (Level of Evidence: C)

5.1.3. Platelet Function Testing

Class IIb
1. Platelet function testing may be considered in patients at high risk for poor clinical outcomes.434 (Level of Evidence: C)
2. In patients treated with clopidogrel with high platelet reactivity, alternative agents, such as prasugrel or ticagrelor, might be considered.434 (Level of Evidence: C)

Class III: NO BENEFIT
1. The routine clinical use of platelet function testing to screen patients treated with clopidogrel who are undergoing PCI is not recommended.434 (Level of Evidence: C)

5.2. Restenosis

Class I
1. Patients who develop clinical restenosis after balloon angioplasty should be treated with BMS or DES if anatomic factors are appropriate and if the patient is able to comply with and tolerate DAPT.435 (Level of Evidence: B)
2. Patients who develop clinical restenosis after BMS should be treated with DES if anatomic factors are appropriate and the patient is able to comply with and tolerate DAPT.436–438 (Level of Evidence: A)

Class IIa
1. IVUS is reasonable to determine the mechanism of stent restenosis.254 (Level of Evidence: C)

Class IIb
1. Patients who develop clinical restenosis after DES may be considered for repeat PCI with balloon angioplasty, BMS, or DES containing the same drug or an alternative antiproliferative drug if anatomic factors are appropriate and the patient is able to comply with and tolerate DAPT.254 (Level of Evidence: C)

5.2.1. Exercise Testing

Class IIa
1. In patients entering a formal cardiac rehabilitation program after PCI, treadmill exercise testing is reasonable. (Level of Evidence: C)

Class III: NO BENEFIT
1. Routine periodic stress testing of asymptomatic patients after PCI without specific clinical indications should not be performed.403 (Level of Evidence: C)

5.2.2. Cardiac Rehabilitation

Class I
1. Medically supervised exercise programs (cardiac rehabilitation) should be recommended to patients after PCI, particularly for moderate- to high-risk patients for whom supervised exercise training is warranted.404–412 (Level of Evidence: A)

6. Quality and Performance Considerations: Recommendations

6.1. Quality and Performance

Class I
1. Every PCI program should operate a quality-improvement program that routinely 1) reviews quality and outcomes of the entire program; 2) reviews results of individual operators; 3) includes risk adjustment; 4) provides peer review of difficult or complicated cases; and 5) performs random case reviews. (Level of Evidence: C)
2. Every PCI program should participate in a regional or national PCI registry for the purpose of benchmarking its outcomes against current national norms. (Level of Evidence: C)

6.2. Certification and Maintenance of Certification

Class IIa
1. It is reasonable for all physicians who perform PCI to participate in the American Board of Internal Medicine interventional cardiology board certification and maintenance of certification program. (Level of Evidence: C)

6.3. Operator and Institutional Competency and Volume

Class I
1. Elective/urgent PCI should be performed by operators with an acceptable annual volume (≥75 procedures) at high-volume centers (>400 procedures) with on-site cardiac surgery.439,440 (Level of Evidence: C)
2. Elective/urgent PCI should be performed by operators and institutions whose current risk-adjusted outcomes statistics are comparable to those reported in contemporary national data registries. (Level of Evidence: C)
3. Primary PCI for STEMI should be performed by experienced operators who perform more than 75 elective PCI procedures per year and, ideally, at least 11 PCI procedures for STEMI per year. Ideally, these procedures should be performed in institutions that perform more than 400 elective PCIs per year and more than 36 primary PCI procedures for STEMI per year.439,441–444 (Level of Evidence: C)
Class IIa

1. It is reasonable that operators with acceptable volume (≥75 PCI procedures per year) perform elective/urgent PCI at low-volume centers (200 to 400 PCI procedures per year) with on-site cardiac surgery.\(^{39}\) \textit{(Level of Evidence: C)}

2. It is reasonable that low-volume operators (<75 PCI procedures per year) perform elective/urgent PCI at high-volume centers (>400 PCI procedures per year) with on-site cardiac surgery. Ideally, operators with an annual procedure volume of fewer than 75 procedures per year should only work at institutions with an activity level of more than 600 procedures per year. Operators who perform fewer than 75 procedures per year should develop a defined mentoring relationship with a highly experienced operator who has an annual procedural volume of at least 150 procedures. \textit{(Level of Evidence: C)}

Class IIb

1. The benefit of primary PCI for STEMI patients eligible for fibrinolysis when performed by an operator who performs fewer than 75 procedures per year (<11 PCIs for STEMI per year) is not well established. \textit{(Level of Evidence: C)}

Class III: NO BENEFIT

1. It is not recommended that elective/urgent PCI be performed by low-volume operators (<75 procedures per year) at low-volume centers (200 to 400 procedures per year) with or without on-site cardiac surgery. An institution with a volume of fewer than 200 procedures per year, unless in a region that is underserved because of geography, should carefully consider whether it should continue to offer this service.\(^{39}\) \textit{(Level of Evidence: C)}

References


17. Dzavik V, Ghalia WA, Norris C, et al. Long-term survival in 11,661 patients with multivessel coronary artery disease in the era of stenting: a report from the alberta provincial project for outcome assessment in...


Sanborn TA, Sleeper LA, Bates ER, et al. Impact of thrombolysis, intra-aortic balloon pump counterpulsation, and their combination in cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK Trial Registry. Should we emergently revascularize...


275. Gurbel PA, Blieden KP, Zaman KA, et al. Clopidogrel loading with epifibatide to arrest the reactivity of platelets: results of the Clopi-
277. van der Heijden DJ, Westendorp IC, Riezebos KK, et al. Lack of
efficacy of clopidogrel pre-treatment in the prevention of myocardial damage after elective stent implantation. J Am Coll Cardiol. 2004;
44:20–2.
278. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopi-
1045–57.
280. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin
in 45,852 patients with acute myocardial infarction: randomised
clopidogrel and aspirin followed by long-term therapy in patients
undergoing percutaneous coronary intervention: the PCI-CURE study.
bleeding complications after different doses of aspirin in 192,036
patients enrolled in 31 randomized controlled trials. Am J Cardiol.
antiplatelet therapy following percutaneous coronary intervention: a
College of Chest Physicians Evidence-Based Clinical Practice
diovascular disease: the association of aspirin dose and clopidogrel
286. Serenbruun V, Steinshiel SR, Berger PB, et al. Analysis of risk of
bleeding complications after different doses of aspirin in 192,036
patients enrolled in 31 randomized controlled trials. Am J Cardiol.
287. Peters RJ, Mehta SR, Fox KA, et al. Effects of aspirin dose when used
alone or in combination with clopidogrel in patients with acute
 coronary syndromes: observations from the Clopidogrel in Unstable
angina to prevent Recurrent Events (CURE) study. Circulation. 2003;
inferior artery stent implantation for acute myocardial infarction
and long-term survival: a prospective, multicenter, randomized trial com-
paring inferior artery stenting plus abciximab with stenting alone. Cir-
IIIa/IIb receptor blockade with abciximab on clinical and angiographic
restenosis rate after the placement of coronary stents following acute
290. Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with
2003;349:969–76.
IIb/IIIa inhibition with coronary stenting for acute myocardial infarction.
therapy to reperfusion in acute ST-segment elevation myocardial infarction:
a meta-analysis of randomized trials. JAMA. 2005;293:
1759–65.
ST-segment-elevation myocardial infarction undergoing primary
percutaneous coronary intervention after clopidogrel loading: a ran-
294. De Luca G, Navarese E, Marino P. Risk profile and benefits from Gp
IIb/IIIa inhibitors among patients with ST-segment elevation myo-
cardial infarction treated with primary angioplasty: a meta-regression


332. Lincoff AM, Kleiman NS, Kereiakes DJ, et al. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin


null


Appendix 1. Author Relationships With Industry and Other Entities ( Relevant)—2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention

<table>
<thead>
<tr>
<th>Committee Member</th>
<th>Employer/Title</th>
<th>Consultant</th>
<th>Ownership/Partnership/Bureau</th>
<th>Personal Research</th>
<th>Institutional, Organizational, or Other Financial Benefit</th>
<th>Expert Witness</th>
<th>Voting Recusals by Section Number*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glenn N. Levine (Chair)</td>
<td>Baylor College of Medicine-Professor of Medicine; Director, Cardiac Care Unit</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Eric R. Bates (Vice Chair)</td>
<td>University of Michigan-Professor of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>5.7.2</td>
</tr>
<tr>
<td></td>
<td>• Bristol-Myers Squibb</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>5.7.3</td>
<td>5.7.4.1</td>
</tr>
<tr>
<td></td>
<td>• Daiichi-Sankyo</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>5.7.4.2</td>
<td>5.7.4.3</td>
</tr>
<tr>
<td></td>
<td>• Datascopre</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>5.7.4.4</td>
<td>5.7.4.5</td>
</tr>
<tr>
<td></td>
<td>• Eli Lilly</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>6.1</td>
<td>6.1.2</td>
</tr>
<tr>
<td></td>
<td>• Merck</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>6.1.3</td>
<td>6.1.4</td>
</tr>
<tr>
<td>James C. Blankenship (Vice Chair)</td>
<td>Geisinger Medical Center-Director of Cardiology and Cardiac Catheterization</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>2.1</td>
</tr>
<tr>
<td></td>
<td>Laboratories</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>2.2</td>
</tr>
<tr>
<td></td>
<td>• Abiomed</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>2.3</td>
</tr>
<tr>
<td></td>
<td>• AstraZeneca</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>2.9.7</td>
</tr>
<tr>
<td></td>
<td>• Boston Scientific</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>2.11</td>
</tr>
<tr>
<td></td>
<td>• Cordis</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>5.2.4</td>
</tr>
<tr>
<td></td>
<td>• Daiichi-Sankyo</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>5.3</td>
</tr>
<tr>
<td></td>
<td>• Sanofi-aventis</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>5.4.1</td>
</tr>
<tr>
<td>Steven R. Bailey</td>
<td>University of Texas Medical Center-Professor of Medicine and Radiology</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>5.4.2</td>
</tr>
<tr>
<td>John A. Blitt</td>
<td>Munroe Heart-Intervention Cardiologist</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Bojan Cercek</td>
<td>Cedars-Sinai Medical Center-Director, Coronary Care Unit</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Charles E. Chambers</td>
<td>Penn State Milton S. Hershey Medical Center-Professor of Medicine and Radiology</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Stephen G. Ellis</td>
<td>Cleveland Clinic Foundation—Section Head, Invasive and Interventional Cardiology</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>2.2</td>
</tr>
<tr>
<td></td>
<td>• Abbott Vascular</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>2.11</td>
</tr>
<tr>
<td></td>
<td>• Boston Scientific</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>5.7.2</td>
</tr>
<tr>
<td></td>
<td>• Cordis</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>6.1</td>
</tr>
<tr>
<td>Robert A. Guyton</td>
<td>Emory Clinic, Inc.—Professor and Chief, Division of Cardiothoracic Surgery</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>2.1</td>
</tr>
<tr>
<td></td>
<td>• Edwards Lifesciences</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>2.2</td>
</tr>
<tr>
<td>Steven M. Hollenberg</td>
<td>Cooper University Hospital—Director, Coronary Care Unit</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>2.3</td>
</tr>
<tr>
<td>Umesh N. Khut</td>
<td>CV Research Innovations, LLC—President/CEO</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>2.9.7</td>
</tr>
<tr>
<td>Richard A. Lange</td>
<td>University of Texas Health Science Center at San Antonio—Professor of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>2.11</td>
</tr>
<tr>
<td></td>
<td>• Eisai</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>5.2.4</td>
</tr>
<tr>
<td></td>
<td>• Merck†</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>5.3</td>
</tr>
</tbody>
</table>

(Continued)
<table>
<thead>
<tr>
<th>Committee Member</th>
<th>Employer/Title</th>
<th>Consultant</th>
<th>Ownership/Partnership/Principal</th>
<th>Personal Research</th>
<th>Institutional, Organizational, or Other Financial Benefit</th>
<th>Expert Witness</th>
<th>Voting Recusals by Section Number*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laura Mauri</td>
<td>Brigham and Women’s Hospital—Associate Professor of Medicine, Harvard Medical School</td>
<td>● Abbott, ● Conor MedSystems (Johnson &amp; Johnson) ● Cordis ● Medtronic</td>
<td>None</td>
<td>None</td>
<td>● Lutonix</td>
<td>● Abbott</td>
<td>2.9.7</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5.2.3</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5.3</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5.4.2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5.5.1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5.5.2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5.5.4</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5.5.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5.6</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5.7.2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5.7.3</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5.8.2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5.8.3</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5.8.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5.11</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>6.1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>6.1.2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>6.1.3</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>6.2</td>
</tr>
<tr>
<td>Roxana Mehran</td>
<td>Columbia University Medical Center—Associate Professor of Medicine; Director, Data Coordinating Analysis Center</td>
<td>● Abbott Vascular ● Abiomed ● AlphaMedical ● AstraZeneca ● Bracco ● BMS/sanofiaventis ● DataScope ● Eli Lilly/Daichi-Sankyo ● Guerbet ● The Medicines Company ● Medtronic Vascular ● St. Jude</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5.1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5.2.4</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5.3</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5.4.1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5.4.2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5.5.1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5.5.2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5.6</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5.7.2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5.7.3</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5.7.4.1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5.7.4.2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5.7.4.3</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5.7.4.4</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5.7.4.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5.8.3</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5.8.4</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5.11</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>6.1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>6.1.2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>6.1.3</td>
</tr>
<tr>
<td>Issam D. Moussa</td>
<td>Mayo Clinic—Professor of Medicine; Chair, Division of Cardiovascular Diseases</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Debabrata Mukherjee</td>
<td>Texas Tech University—Chief, Cardiovascular Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

(Continued)
This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$10 000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted.

According to the ACCF/AHA, a person has a relevant relationship IF: a) The relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; or b) The company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document, or makes a competing drug or device addressed in the document; or c) The person or a member of the person’s household has a reasonable potential for financial, professional, or other personal gain or loss as a result of the issues/content addressed in the document.

*Writing committee members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply. Section numbers apply to the full-text guideline.
†Significant relationship.
## Appendix 2. Reviewer Relationships With Industry and Other Entities (Relevant)—2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention

<table>
<thead>
<tr>
<th>Peer Reviewer</th>
<th>Representation</th>
<th>Consultant</th>
<th>Speaker’s Bureau</th>
<th>Ownership/Partnership/Principal</th>
<th>Personal Research</th>
<th>Institutional, Organizational, or Other Financial Benefit</th>
<th>Expert Witness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deepak L. Bhatt</td>
<td>Official Reviewer—AHA</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>● AstraZeneca*</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>● Bristol-Myers Squibb*</td>
<td></td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>● Eli Lilly</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>● Ethicon*</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>● The Medicines Company*</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>● PLX Pharma†</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>● Sanofi-aventis*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mauricio G. Cohen</td>
<td>Official Reviewer—AHA</td>
<td>None</td>
<td>● Terumo Medical</td>
<td>None</td>
<td></td>
<td>● Invitrox*</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>None</td>
<td></td>
<td>None</td>
</tr>
<tr>
<td>John P. Erwin III</td>
<td>Official Reviewer—ACCF/AHA Task Force on Performance Measures</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td></td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kirk Garratt</td>
<td>Official Reviewer—SCAI</td>
<td>● AstraZeneca*</td>
<td>● Boston Scientific</td>
<td>● Abbott Vascular</td>
<td></td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td>● Momenta Pharma</td>
<td>● Cordis/Johnson &amp; Johnson</td>
<td>● Medtronic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>● Xoma</td>
<td>● The Medicines Company</td>
<td>● The Medicines Company</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Steven L. Goldberg</td>
<td>Official Reviewer—SCAI</td>
<td>None</td>
<td>● AGA</td>
<td>● Bristol-Myers Squibb</td>
<td>● Wyeth*</td>
<td>None</td>
<td>● Plaintiff, patient litigation, 2010</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>● Sanofi-aventis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alice K. Jacobs</td>
<td>Official Reviewer—ACCF/AHA Task Force on Practice Guidelines</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td></td>
<td>● Abbott Vascular*</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>● Abiomed*</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>● Accumetrics*</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>● Cardiovascular Research Foundation (DSMB)†</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>● Harvard Clinical Research Institute†</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>● TIMI Study Group (DSMB)†</td>
<td>None</td>
</tr>
<tr>
<td>G.B. John Mancini</td>
<td>Official Reviewer—ACCF Board of Governors</td>
<td>● GlaxoSmithKline</td>
<td>None</td>
<td>None</td>
<td></td>
<td>● Merck*</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td>● Merck</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>● Pfizer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>● Sanofi-aventis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>W. Douglas Weaver</td>
<td>Official Reviewer—ACCF Board of Trustees</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td></td>
<td>● Boehringer Ingelheim (DSMB)</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>● Boston Scientific (DSMB)</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>● Duke Clinical Research Institute (Johnson &amp; Johnson/Schering Plough)*</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>● GlaxoSmithKline</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>● NHLBI (DSMB)</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>● TIMI Study Group (Johnson &amp; Johnson/Bayer-DSMB)</td>
<td>None</td>
</tr>
<tr>
<td>Thomas M. Bashore</td>
<td>Content Reviewer</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td></td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Christopher E. Butler</td>
<td>Content Reviewer</td>
<td>● Abbott Vascular</td>
<td>None</td>
<td>None</td>
<td></td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>James A. Burke</td>
<td>Content Reviewer—ACCF Interventional Scientific Council</td>
<td>● Toshiba Medical</td>
<td>None</td>
<td>None</td>
<td></td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td>● Edwards Lifesciences</td>
<td>None</td>
<td>None</td>
<td></td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>John G. Byrne</td>
<td>Content Reviewer—ACCF Surgeons’ Scientific Council</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td></td>
<td>● Novadaq Technologies*</td>
<td>None</td>
</tr>
<tr>
<td>T. Bruce Ferguson</td>
<td>Content Reviewer—ACCF Surgeons’ Scientific Council</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td></td>
<td>● Novadaq Technologies*</td>
<td>None</td>
</tr>
<tr>
<td>Victor A. Ferrari</td>
<td>Content Reviewer</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td></td>
<td>● NHLBI (DSMB)†</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>● National Institute for Aging/NIH (DSMB)†</td>
<td>None</td>
</tr>
</tbody>
</table>

(Continued)
This table represents the relationships of reviewers with industry and other entities that were disclosed at the time of peer review and determined to be relevant. It does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of \( \geq 5\% \) of the voting stock or share of the business entity, or ownership of \( \geq \$10000 \) of the fair market value of the business entity; or if funds received by the person from the business entity exceed \( 5\% \) of the person’s gross income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Names are listed in alphabetical order within each category of review.

According to the ACCF/AHA, a person has a relevant relationship if: a) The relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; or b) The company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document, or makes a competing drug or device addressed in the document; or c) The person or a member of the person’s household has a reasonable potential for financial, professional, or other personal gain or loss as a result of the issues/content addressed in the document.

*Significant relationship.
†No financial benefit.

ACCF indicates American College of Cardiology Foundation; AHA, American Heart Association; DSMB, data safety and monitoring board; NHLBI, National Heart, Lung, and Blood Institute; NIH, National Institutes of Health; SCAI, Society for Cardiovascular Angiography and Interventions; and TIMI, Thrombolysis In Myocardial Infarction.

<table>
<thead>
<tr>
<th>Peer Reviewer</th>
<th>Representation</th>
<th>Consultant</th>
<th>Speaker’s Bureau</th>
<th>Ownership/Partnership/Principal</th>
<th>Personal Research</th>
<th>Institutional, Organizational, or Other Financial Benefit</th>
<th>Expert Witness</th>
</tr>
</thead>
<tbody>
<tr>
<td>John G. Harold</td>
<td>Content Reviewer</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Biswajit Kar</td>
<td>Content Reviewer</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Morton J. Kern</td>
<td>Content Reviewer</td>
<td>● Infrarex</td>
<td>● St. Jude Medical*</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Spencer B. King III</td>
<td>Content Reviewer</td>
<td>● Celonova Biosciences†</td>
<td>None</td>
<td>None</td>
<td>● Merck (DSMB)</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Frederick G. Kushner</td>
<td>Content Reviewer</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>● Novartis†</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>David J. Maron</td>
<td>Content Reviewer</td>
<td>None</td>
<td>None</td>
<td>● Cardiovascular Care Affiliates*</td>
<td>None</td>
<td>● Plaintiff, acute coronary syndrome, 2010</td>
<td>None</td>
</tr>
<tr>
<td>Douglass A. Morrison</td>
<td>Content Reviewer</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>● Defendant, stent perforation, 2010</td>
<td>None</td>
</tr>
<tr>
<td>Thomas C. Piemonte</td>
<td>Content Reviewer—ACCF Board of Governors</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Peter K. Smith</td>
<td>Content Reviewer</td>
<td>● Eli Lilly</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Sidney C. Smith</td>
<td>Content Reviewer</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Richard W. Snyder</td>
<td>Content Reviewer—ACCF Board of Governors</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>● Hospital Corporation of America</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Patrick L. Whitlow</td>
<td>Content Reviewer</td>
<td>● Edwards Lifesciences*</td>
<td>None</td>
<td>None</td>
<td>● ICON</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>David G. Williams</td>
<td>Content Reviewer</td>
<td>● Light Lab/St. Jude Medical</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>R. Scott Wright</td>
<td>Content Reviewer</td>
<td>● Hoffman LaRoche*</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>


_Circulation_. 2011;124:2574-2609; originally published online November 7, 2011; doi: 10.1161/CIR.0b013e31823a5596

_Circulation_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2011 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/124/23/2574

An erratum has been published regarding this article. Please see the attached page for:
/content/125/8/e411.full.pdf

Data Supplement (unedited) at:
http://circ.ahajournals.org/content/suppl/2011/11/07/CIR.0b013e31823a5596.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation_ is online at:
http://circ.ahajournals.org//subscriptions/
Correction

In the article by Levine et al, “2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary,” which published ahead of print on November 7, 2011, and appeared in the December 6, 2011, issue of the journal (Circulation. 2011;124:2574–2609), several corrections were needed:

1. On page 2591, in the first column, first paragraph under section “4.9. Periprocedural Myocardial Infarction Assessment,” the last 2 lines of the Class I recommendation read, “. . . creatinine kinase-MB and troponin I or T should be measured. . . .” They have been changed to read, “. . . creatine kinase-MB and/or troponin I or T should be measured. . . .” The corrected recommendation now reads,

In patients who have signs or symptoms suggestive of myocardial infarction during or after PCI or in asymptomatic patients with significant persistent angiographic complications (eg, large side-branch occlusion, flow-limiting dissection, no-reflow phenomenon, or coronary thrombosis), creatine kinase-MB and/or troponin I or T should be measured. (Level of Evidence: C).

2. On page 2591, in the first column, second paragraph under section “4.9. Periprocedural Myocardial Infarction Assessment,” the parenthetical expression in the first and second lines of the Class IIb recommendation read, “. . . (creatine kinase-MB and/or troponin I or T). . . .” It has been changed to read, “. . . (creatine kinase-MB and/or troponin I or T). . . .” The corrected recommendation now reads,

Routine measurement of cardiac biomarkers (creatine kinase-MB and/or troponin I or T) in all patients after PCI may be reasonable. (Level of Evidence: C).

These corrections have been made to the current online version of the article, which is available at http://circ.ahajournals.org/content/124/23/2574.
# 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention—ONLINE AUTHOR LISTING OF COMPREHENSIVE RELATIONSHIPS WITH INDUSTRY AND OTHERS (October 2011)

<table>
<thead>
<tr>
<th>Committee Member</th>
<th>Employer/Title</th>
<th>Consultant</th>
<th>Speaker’s Bureau</th>
<th>Ownership/Partnership/Principal</th>
<th>Personal Research</th>
<th>Institutional, Organizational or Other Financial Benefit</th>
<th>Expert Witness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glenn N. Levine</td>
<td>Baylor College of Medicine—Professor of Medicine; Director, Cardiac Care Unit</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>(Chair)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Eric R. Bates    | University of Michigan—Professor of Medicine | • Bristol-Myers Squibb  
• Daiichi Sankyo  
• Dataspore  
• Eli Lilly  
• Merck  
• sanofi-aventis  
• Takeda | None | None | None | None | None | None |
| (Vice Chair)     |                |            |                  |                                 |                  |                                                        |                |
| James C. Blankenship | Geisinger Medical Center—Director of Cardiology and Cardiac Catheterization Laboratory | None | None | None | • Abiomed  
• AstraZeneca  
• Boston Scientific  
• Conor Medsystems  
• Kai Pharmaceutical  
• Novartis  
• Schering-Plough | None | None | None |
<p>| (Vice Chair)     |                |            |                  |                                 |                  |                                                        |                |
| Steven R. Bailey | University of Texas Medical Center—Professor of Medicine and Radiology | • Volcano | None | None | • Boston Scientific | None | None |
| John A. Bittl    | Munroe Heart—Interventional Cardiologist | None | None | None | None | None | None |
| Bojan Cercek     | Cedars-Sinai Medical Center—Director, Coronary Care Unit | None | None | None | None | None | None |
| Charles E. Chambers | Penn State Milton S. Hershey Medical | None | None | None | None | None | None |</p>
<table>
<thead>
<tr>
<th>Name</th>
<th>Institution/Position</th>
<th>Companies/Institutions</th>
<th>Relationships and Roles</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stephen G. Ellis</td>
<td>Cleveland Clinic Foundation—Director, Sones Cardiac Catheterization Laboratory</td>
<td>• Abbott Vascular&lt;br&gt;• AcelleRX Therapeutics&lt;br&gt;• Boston Scientific&lt;br&gt;• CardioDX&lt;br&gt;• Celer Diagnost&lt;br&gt;• Cordis&lt;br&gt;• Viacor</td>
<td>None None None None None</td>
</tr>
<tr>
<td>Robert A. Guyton</td>
<td>Emory Clinic, Inc—Professor and Chief, Division of Cardiothoracic Surgery</td>
<td>None</td>
<td>None Edwards Lifesciences None None None None</td>
</tr>
<tr>
<td>Steven M. Hollenberg</td>
<td>Cooper University Hospital—Director, Coronary Care Unit</td>
<td>• Eisai</td>
<td>None None None None None None None None</td>
</tr>
<tr>
<td>Umesh N. Khot</td>
<td>CV Research Innovations, LLC—President/CEO</td>
<td>None</td>
<td>None Merck* St. Francis Hospital and Health Centers* None None None None</td>
</tr>
<tr>
<td>Laura Mauri</td>
<td>Brigham &amp; Women’s Hospital—Assistant Professor of Medicine, Harvard Medical School</td>
<td>• Conor Medsystems (Johnson &amp; Johnson)&lt;br&gt;• Cordis</td>
<td>None None Lutonix Abbott Abiomed Boston Scientific Bristol-Myers Squibb Conor Medsystems Cordis Daiichi Sankyo Eli Lilly Medtronic Cardiovascular sanofi-aventis</td>
</tr>
<tr>
<td>Roxana Mehran</td>
<td>Columbia University Medical Center—Associate Professor of Medicine; Director, Data Coordinating Analysis</td>
<td>• Abbott Vascular&lt;br&gt;• Abiomed&lt;br&gt;• Accumetrics&lt;br&gt;• AlphaMedical&lt;br&gt;• AstraZeneca</td>
<td>None None None Endothelix None None None None None</td>
</tr>
</tbody>
</table>

*Defendant*
This table represents all healthcare relationships of committee members with industry and other entities that were reported by authors, including those not deemed to be relevant to this document, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$10,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to [http://www.cardiosource.org/Science-And-Quality/Practice-Guidelines-and-Quality-Standards/Relationships-With-Industry-Policy.aspx](http://www.cardiosource.org/Science-And-Quality/Practice-Guidelines-and-Quality-Standards/Relationships-With-Industry-Policy.aspx) for definitions of disclosure categories or additional information about the ACCF/AHA Disclosure Policy for Writing Committees.

*Indicates significant relationship